| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Musculoskeletal System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Musculoskeletal System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Can-Fite Biopharma Ltd$3.25
-0.02 (-0.61%)
C 59Pipeline Score Undervalued Pharma · Clinical
Market Cap
7.15 M
EPS
-12.45
P/E Ratio
-
Value Trade
62.62 K
-2.58 %
Week
15.84 %
1 Month
-23.6 %
3 Month
-44.88 %
6 Month
-99.19 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
49.03 K
52 Week Range
2.83 - 23.40
% held by Insiders
-
% held by Institutions
6.45 %
Enterprise Value
-1.32 M
Total Shares
2.14 M
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Can-Fite Biopharma Ltd
914Total events
11Upcoming
220Tier-1 (high impact)
2013 – 2044Coverage
Upcoming catalysts 11
2029
T2Other Regulator Milestone
Expected registration for Piclidenoson in canine osteoarthritis in 2029
Event history 903
Jul 6, 2026
▲Enrollment CompletePiclidenosonApprovedTrial
Completed enrolment of first 247 patients in pivotal Phase 3 study for Piclidenoson
moderate-to-severe plaque psoriasissource ↗
Q3 2026
◆Topline ReadoutPiclidenosonApprovedClinical Data
Top-line results expected in Q3 2026
osteoarthritis in dogssource ↗
Q3 2026
◆Topline ReadoutNamodenosonClinical Data
Top-line efficacy data expected in Q3 2026
pancreatic cancersource ↗
Jun 22, 2026
▲PublicationPresentation
Peer-reviewed article published on A3AR agonists Piclidenoson and Namodenoson in Biomolecules Journal
Jun 22, 2026
Jun 17, 2026
◆Topline ReadoutPiclidenosonApprovedClinical Data
Piclidenoson Phase 3 topline results reported for psoriasis
psoriasissource ↗
Jun 17, 2026
▲Trial InitiationPiclidenosonApprovedTrial
Piclidenoson pivotal Phase 3 trial commenced for psoriasis
psoriasissource ↗
Jun 17, 2026
◆Trial InitiationNamodenosonTrial
Namodenoson Phase IIb study ongoing for pancreatic cancer
pancreatic cancersource ↗
Jun 2, 2026
▲Enrollment CompleteNamodenosonTrial
Enrollment completed in Phase 2a pancreatic cancer study of namodenoson
pancreatic cancersource ↗
Jun 2026
◆Oral PresentationNamodenosonPresentation
Phase 2b study design to be discussed at BIO International Convention
advanced pancreatic cancersource ↗
May 18, 2026
▲PublicationPiclidenosonApprovedPresentation
Publication of peer-reviewed article on Piclidenoson for canine osteoarthritis in Frontiers in Veterinary Science
canine osteoarthritissource ↗
May 13, 2026
▲Topline ReadoutNamodenosonClinical Data
Phase 2a topline data showed favorable safety and clinical activity
advanced pancreatic adenocarcinomasource ↗
Drug Pipeline Intelligence
C59
Pipeline Score $108M
Pipeline ValueUndervalued
Valuation Signal4
Drugs Scored15.0x
rNPV / MCap Top 87%
Micro Cap (rank 119 of 911)
Percentile RankCan-Fite Biopharma Ltd carries a moderate pipeline score (59/100), with $10.6B risk-adjusted pipeline value, led by CF101 in Plaque Psoriasis (Phase 3), across $122B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| piclidenoson Small molecule | Plaque Psoriasis | Phase 3 | NCT06643260 | 58% | $5.0B | NOT YET_RECRUITING | 705 | FAST | B (63) | Jun 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Piclidenoson | psoriasis | Phase 3 | 2026-06-17 | Can-Fite recently reported topline results from a Phase 3 trial of Piclidenoson for psoriasis, indicating significant efficacy, although specific efficacy percentages, ORR, PFS/OS, or response rates were not detailed in the press release. Read More | Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 Read More | |
Piclidenoson | psoriasis | Phase 3 | 2026-06-17 | Can-Fite recently reported topline results from a Phase 3 trial of Piclidenoson for psoriasis, indicating significant efficacy, although specific efficacy percentages, ORR, PFS/OS, or response rates were not detailed in the press release. Read More | Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 Read More | |
Piclidenoson | psoriasis | Phase 3 | 2026-06-17 | Can-Fite recently reported topline results from a Phase 3 trial of Piclidenoson for psoriasis, indicating significant efficacy, although specific efficacy percentages, ORR, PFS/OS, or response rates were not detailed in the press release. Read More | Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CANF
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CANF Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CANFCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite BioPharma has completed patient enrolment for its pivotal Phase 3 study of Piclidenoson, targeting moderate-to-severe plaque psoriasis. The study, which involves 247 patients, is set for an interim analysis under FDA and EMA protocols. Results are anticipated in Q4 2026 or Q1 2027, highlighting the drug's potential as an oral treatment option.
Read more →CANF▲ +55.9%on this newsshared move
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite BioPharma's Phase 2a study of Namodenoson in advanced pancreatic cancer has achieved its primary safety endpoint and shown promising survival outcomes. The study involved 20 patients, with significant survival rates observed in those treated with Namodenoson. The company plans to further investigate the drug in a Phase 2b study in combination with chemotherapy.
Read more →CANF▼ -6.5%on this news· ran to +57% by day 3shared move
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite BioPharma has received a patent allowance in Japan for its drug Namodenoson, aimed at treating obesity and metabolic disorders. This patent strengthens the company's intellectual property portfolio, which already includes protections in major markets. Namodenoson's unique mechanism of action and established safety profile position it favorably in the expanding obesity therapeutics market.
Read more →CANFCan-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite BioPharma Ltd. announced the publication of a peer-reviewed article highlighting the therapeutic potential of its drug candidates, Piclidenoson and Namodenoson. The article reviews evidence from various research groups, demonstrating the efficacy of A3 adenosine receptor agonists in treating multiple diseases. This publication underscores Can-Fite's strategy to leverage A3AR agonists for diverse therapeutic applications.
Read more →CANFCan-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite BioPharma will present its late-stage clinical pipeline at the BIO International Convention 2026 in San Diego. The company aims to engage in partnering meetings to explore licensing and commercialization opportunities for its drug candidates, including Namodenoson and Piclidenoson, which are in pivotal Phase III studies. The event is crucial for Can-Fite to establish strategic collaborations in oncology and inflammatory diseases.
Read more →CANFCan-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
Can-Fite BioPharma has reported positive clinical observations from its Phase 2a study of namodenoson in pancreatic cancer, highlighting its ability to inhibit the RAS signaling pathway. The study has shown prolonged disease control in several patients, including one who has been on therapy for approximately 16 months. Namodenoson is noted for its multi-pathway mechanism and favorable safety profile.
Read more →CANFScientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market Ramat Gan, Israel
Can-Fite BioPharma announced the publication of positive findings regarding Piclidenoson for treating canine osteoarthritis in the journal Frontiers in Veterinary Science. The study demonstrated significant improvements in mobility and pain assessments in dogs, supporting its development as a disease-modifying therapy. Vetbiolix, under a licensing agreement with Can-Fite, is progressing with advanced clinical studies of Piclidenoson, which represents a considerable commercial opportunity in the veterinary market, estimated to be worth billions.
Read more →CANF▲ +7.4%on this newsshared move
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Can-Fite BioPharma is advancing its pancreatic cancer program into a Phase 2b study of Namodenoson in combination with immunotherapy, following positive results from a Phase 2a trial. The Phase 2a study showed a favorable safety profile and clinical activity, with some patients on treatment for over 16 months. The company plans to discuss the study design at the BIO International Convention while exploring partnerships with oncology firms.
Read more →CANF▲ +6.7%on this news
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Can-Fite BioPharma Ltd. announced positive results from its Phase 2a study of namodenoson for advanced pancreatic cancer, showing clinical activity and a favorable safety profile. Key findings included stable disease in over 30% of evaluable patients and 35% remaining on therapy, with one individual extending treatment beyond 16 months. The trial suggests namodenoson may offer durable benefits in this challenging patient population. Full efficacy analyses and additional results are anticipated in the coming months.
Read more →CANFNOTICE OF 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 28, 2026 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2026 Annual General Meeting of Shareholders will be held on
Can-Fite BioPharma Ltd. has announced its 2026 Annual General Meeting (AGM) scheduled for May 28, 2026. The agenda includes re-electing a board member, increasing authorized share capital, granting options to key executives, and appointing an auditing firm. Shareholders are encouraged to attend and vote on the proposals. The announcement aims to inform and invite participation in important company decisions.
Read more →CANFCan-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite BioPharma's partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for treating osteoarthritis in dogs. The study involves 118 dogs and aims to assess symptom severity and mobility over 90 days. Top-line results are anticipated in Q3 2026, with potential revenues of up to $325 million from the licensing agreement with Vetbiolix.
Read more →CANFCan-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Can-Fite BioPharma reported its 2025 financial results, highlighting significant clinical advancements, including a successful Phase 2a study in pancreatic cancer and a patient with advanced HCC achieving over nine years of cancer-free survival. The company continues to develop its lead drug, Namodenoson, which has received Orphan Drug and Fast Track designations. However, financial results showed a decrease in revenues and an increased net loss compared to the previous year.
Read more →CANFCan-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Can-Fite BioPharma has announced the allowance of its patent application for Namodenoson by the Israeli Patent Office, which targets obesity treatment. The patent strengthens their intellectual property portfolio amidst the growing metabolic therapeutics market. Namodenoson has shown the potential to offer a differentiated mechanism of action in obesity treatment, unlike current therapies. Despite these advancements, Can-Fite acknowledges the challenges posed by funding uncertainties, regulatory hurdles, and external political factors.
Read more →CANF▼ -42.1%on this news· ran to -61% by day 3
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Can-Fite BioPharma has entered into an agreement for the immediate exercise of warrants, allowing for the purchase of 795,869 ADSs at a reduced price of $5.00 each. This move is expected to generate approximately $4.0 million in gross proceeds, which will be allocated towards research, development, and general corporate purposes. The company has also issued new warrants for additional ADSs.
Read more →CANF▲ +20.4%on this newsshared move
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Can-Fite BioPharma announced that its Phase IIa study of namodenoson in advanced pancreatic cancer met its primary safety endpoint, showing good tolerability among patients. The study involved 20 patients who had previously undergone systemic therapies. While secondary endpoints on overall survival are still being evaluated, the results support further clinical evaluation of namodenoson.
Read more →CANFCan-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Can-Fite BioPharma announced a peer-reviewed study demonstrating the anti-obesity effects of its lead drug candidate, namodenoson. The study showed that namodenoson significantly inhibits adipocyte proliferation and reduces weight gain in a high-fat diet model. This publication expands the drug's potential therapeutic profile, supporting its evaluation for obesity treatment.
Read more →CANFCan-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Can-Fite BioPharma has received a Canadian patent allowance for Namodenoson, an A3 adenosine receptor agonist, as an anti-obesity therapy. This patent complements existing patents in the U.S. and Australia, enhancing intellectual property protection. Namodenoson has shown a favorable safety profile and potential for weight loss in clinical studies, contributing to Can-Fite's strategic expansion in the obesity treatment market.
Read more →CANF▲ +5.2%on this newsshared move
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
Can-Fite BioPharma announced a successful liver transplantation in a patient with advanced decompensated liver cirrhosis after treatment with Namodenoson. The drug provided clinical stabilization, enabling the patient to remain eligible for transplantation. This case highlights the potential of Namodenoson as a supportive treatment for patients awaiting liver transplants.
Read more →CANFNOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 3, 2026 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that Special General Meeting of Shareho
Can-Fite BioPharma Ltd. has announced a Special General Meeting for shareholders and ADS holders to take place on March 3, 2026, at their office in Ramat Gan, Israel. Shareholders are encouraged to attend or vote via proxies if unable to be present. The agenda includes proposals by the Board of Directors, who unanimously recommends support for all items. Shareholders eligible for voting must be on record as of February 5, 2026.
Read more →CANFCan-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
Can-Fite BioPharma has completed patient enrollment in its Phase 2a clinical trial for Namodenoson, targeting advanced pancreatic adenocarcinoma. The study, which focuses on safety and efficacy, has shown a favorable safety profile thus far. Results are anticipated in Q3 2026, marking a significant milestone for the drug's development.
Read more →CANF▲ +18.6%on this news
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Can-Fite BioPharma has received a patent from the Brazilian Patent Office for its A3 adenosine receptor agonists aimed at treating sexual dysfunction. This patent enhances the company's intellectual property in a key market, supporting its ongoing clinical and preclinical programs. The company is also exploring strategic opportunities in Latin America to leverage this patent.
Read more →CANF▼ -25%on this newsshared move
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
Can-Fite BioPharma Ltd. announced a 1-for-3,000 reverse split of its ordinary shares following shareholder approval. The split will be effective on January 2, 2026, with a corresponding change in the ADS ratio from 1:300 to 1:2. This move aims to consolidate shares and may impact the trading price of ADSs. The company reassured that shareholder ownership percentages will remain unchanged, barring fractional shares.
Read more →CANF▲ +9.1%on this news
Can-Fite Provides Update on Clinical and Financial Status
Can-Fite BioPharma Ltd. has provided an update on its clinical and financial activities, announcing ongoing Phase III trials for its drug candidates Namodenoson and Piclidenoson. Namodenoson is being evaluated for advanced hepatocellular carcinoma and metabolic dysfunction-associated steatohepatitis, while Piclidenoson is under investigation for psoriasis. The company holds a cash reserve of $6.45 million and recently secured additional funding through public offerings. Positive interim analysis results could facilitate conditional FDA and EMA approvals for Namodenoson as development continues.
Read more →CANFCan-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Can-Fite BioPharma Ltd. announced that CEO Motti Farbstein will present at the NobleCon21 conference on December 3, 2025. The presentation will cover advancements in the company's drug pipeline, including significant out-licensing agreements. Can-Fite is focused on treating oncological and inflammatory diseases with its lead candidates in late-stage trials.
Read more →CANF▲ +12%on this newsshared move
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
Can-Fite BioPharma will participate in the BioFIT 2025 conference to explore new veterinary partnerships for Namodenoson, its Phase III cancer drug. The company aims to leverage its previous success at BioFIT, where it formed a lucrative partnership for Piclidenoson. Namodenoson has demonstrated promising results in human trials and is considered a strong candidate for veterinary oncology.
Read more →CANF▼ -6.9%on this newsshared move
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
Can-Fite BioPharma has received a Notice of Allowance for its patent on CF602, a treatment for erectile dysfunction, particularly in diabetic patients. This patent extends protection in Brazil, complementing existing patents in the U.S. and Europe. CF602's unique mechanism may address the needs of non-responders to current ED medications, potentially filling a significant gap in the market.
Read more →CANF▲ +5%on this newsshared move
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
Can-Fite BioPharma announced that a patient with advanced liver cancer has survived for nine years following treatment with Namodenoson, demonstrating a complete response. The drug is currently undergoing a pivotal Phase III clinical trial for advanced hepatocellular carcinoma (HCC), with enrollment in Israel, Europe, and the U.S. Namodenoson has received Orphan Drug status and Fast Track designation from regulatory authorities, highlighting its potential as a promising treatment for HCC. The company's broader clinical development includes trials for other conditions, suggesting an expanding portfolio in oncology and inflammatory diseases.
Read more →CANFNOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 3, 2025 To the shareholders and American Depositary Share ("ADS") holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that S
Can-Fite BioPharma Ltd. has announced a Special General Meeting to be held on November 3, 2025. The agenda includes a proposal to increase the authorized share capital by 22 billion shares, resulting in a total of 42 billion authorized shares, and a reverse stock split at a ratio of 1 for 3,000 ordinary shares. Shareholders and ADS holders eligible to vote must do so by the close of business on October 9, 2025, and the Board of Directors recommends voting in favor of the proposals.
Read more →CANFCan-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
Can-Fite BioPharma announced a significant clinical finding where a patient with decompensated liver cirrhosis experienced complete resolution of esophageal varices after treatment with Namodenoson. This outcome, confirmed by endoscopic evaluation, suggests a potential disease-modifying effect of the drug. The case may provide valuable insights for Namodenoson's ongoing clinical development.
Read more →CANFCan-Fite Reports H1 2025 Financial Results and Clinical Update
Can-Fite BioPharma Ltd. reported its H1 2025 financial results and clinical updates, highlighting significant milestones in its drug candidates, Namodenoson and Piclidenoson. The Phase 2a study for Namodenoson in pancreatic cancer achieved over 50% enrollment, while Piclidenoson showed promise for treating vascular dementia. Despite these advancements, the company faced a 36.07% decrease in revenue and an increased net loss.
Read more →CANFOPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and th
Can-Fite BioPharma Ltd has released its financial data and an operational review amid ongoing challenges, including a history of financial losses and a need for further capital. The company is advancing its drug pipeline, featuring CF101 and CF102, aimed at treating various diseases such as psoriasis and advanced liver cancer. While the market presents significant opportunities, the company faces uncertainties related to cash flow and geopolitical risks impacting operations.
Read more →CANF▼ -5.3%on this news
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite BioPharma has reached over 50% enrollment in its Phase 2a trial of Namodenoson for pancreatic cancer. The study focuses on safety, clinical activity, and pharmacokinetics in patients with advanced pancreatic adenocarcinoma. Namodenoson has shown a favorable safety profile and is also being evaluated for other cancers.
Read more →CANF▼ -16.3%on this newsshared move
Can-Fite Announces Up To $15.0 Million Public Offering
Can-Fite BioPharma Ltd. has announced a public offering to raise up to $15 million, with $5 million upfront and an additional $10 million possible through short-term warrants. The offering, priced at $0.60 per ADS, is expected to close on July 29, 2025. Proceeds will support research, development, and general corporate purposes.
Read more →CANF▼ -28.4%on this newsshared move
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Can-Fite BioPharma announced that a study from UCLA demonstrated the efficacy of Piclidenoson in an experimental model of vascular dementia. Conducted by Dr. S. Thomas Carmichael, the study found that Piclidenoson restored tissue integrity and behavioral function in a mouse model. This breakthrough is significant as there are currently no FDA-approved therapies for vascular dementia.
Read more →CANF▲ +6.5%on this news
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Can-Fite BioPharma announced that Dr. Sari Fishman will present an update on their Phase IIa study of Namodenoson for advanced pancreatic cancer at the 2025 BIO International Convention. The trial is evaluating the drug's safety and efficacy in patients who have progressed after prior therapies. The study has enrolled half of the expected patient cohort and has shown promising safety results.
Read more →CANFNOTICE OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2025 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2025 Annual General Meeting of Shareholders will be held o
Can-Fite BioPharma Ltd. has announced its 2025 Annual General Meeting of Shareholders to be held on June 23, 2025. The agenda includes re-election of board members, approval of options for executives, and an increase in authorized share capital. Shareholders and holders of American Depositary Shares (ADS) are entitled to vote, with proxy voting options available for those unable to attend in person. The meeting also includes discussions on the auditor’s report for the financial year ending December 31, 2024.
Read more →CANFCan-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
Can-Fite BioPharma has successfully raised $175 million to advance its lead drug candidates, Namodenoson and Piclidenoson, into pivotal Phase III trials for liver cancer and psoriasis. The funding will also support drug manufacturing and regulatory activities. Both candidates have demonstrated favorable safety and efficacy in prior trials, indicating strong potential for addressing unmet medical needs.
Read more →CANFFollowing FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Can-Fite BioPharma announced that leading U.S. medical centers are seeking FDA approval for compassionate use of Namodenoson to treat pancreatic carcinoma patients. This follows the drug's recent FDA approval for single-patient compassionate use. Can-Fite is also enrolling patients in Israel for a Phase IIa study to evaluate Namodenoson's safety and efficacy in advanced pancreatic cancer.
Read more →CANF▼ -18.5%on this newsshared move
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Can-Fite BioPharma Ltd. announced a registered direct offering of 2.5 million American Depositary Shares at $1.20 each, aiming to raise $3 million. The offering is expected to close around April 15, 2025, and will fund research, development, and general corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
Read more →CANF▼ -17.2%on this newsshared move
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Can-Fite BioPharma Ltd. has announced a forecast of $685 million in potential future revenues from its partnerships, driven by its lead drug candidates, Piclidenoson and Namodenoson. The projections are based on expected regulatory approvals and market launches between 2027 and 2029. Despite the optimistic outlook, the company acknowledges inherent uncertainties in drug development and the need for additional capital.
Read more →CANF▼ -17.2%on this newsshared move
Can-Fite Reports 2024 Financial Results and Clinical Update
Can-Fite BioPharma Ltd. reported 2024 financial results alongside clinical updates on its drug candidates. Notably, Namodenoson demonstrated promising efficacy in treating liver cancer, leading to a complete remission in a patient. The drug received Orphan Drug Designation from the FDA for pancreatic cancer, enhancing its potential market opportunities. Can-Fite is also advancing its drug Piclidenoson for psoriasis into a pivotal Phase 3 trial and is exploring its application in canine osteoarthritis with a partnership for further development.
Read more →CANFCan-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Can-Fite BioPharma Ltd. has announced the initiation of a pivotal Phase 3 study for its oral drug Piclidenoson to treat moderate to severe plaque psoriasis, following an FDA and EMA-approved protocol. The randomized trial will assess the safety and efficacy of Piclidenoson, with patient enrollment expected to begin in Europe, followed by the US and Canada. Success in this trial may lead to a New Drug Application submission to the FDA and a Marketing Authorization Plan submission to the EMA. Piclidenoson is noted for its excellent safety profile and potential effectiveness based on earlier studies.
Read more →CANF▼ -7.3%on this newsshared move
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Can-Fite BioPharma Ltd. announced its partner Vetbiolix is initiating an advanced clinical trial for Piclidenoson, a treatment for canine osteoarthritis. This comes amidst the veterinary market's growth, projected to reach $6.3 billion by 2030. Can-Fite stands to earn $325 million in royalties upon regulatory approval by capturing an estimated 6% market share. The drug has demonstrated a favorable safety profile in prior studies, suggesting its potential effectiveness in treating this condition in dogs.
Read more →CANF▼ -19.4%on this newsshared move
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Can-Fite BioPharma Ltd. has announced the completion of the Phase II study design for its drug Piclidenoson to treat Lowe Syndrome, a rare genetic disease. The open-label study will involve five patients, focusing on the drug's efficacy in improving renal uptake. Previous pre-clinical studies indicate promising results, showing that Piclidenoson may significantly reduce urinary protein loss. The collaboration with Fondazione Telethon adds credibility to the development process.
Read more →CANF▲ +22.4%on this newsshared move
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
Can-Fite BioPharma Ltd. has received FDA approval for compassionate use of Namodenoson in a pancreatic cancer patient. This program allows access to the investigational drug addressing serious conditions for patients not eligible for clinical trials. Namodenoson is also undergoing evaluation in various clinical studies, including Phase III trials for advanced liver cancer, and has received Orphan Drug Designation for pancreatic cancer. The company remains committed to advancing the availability of this treatment amid ongoing clinical evaluation.
Read more →CANFCan-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
Can-Fite BioPharma Ltd. announced the publication of a pivotal article on Namodenoson, highlighting its protective benefits against liver cancer while also safeguarding healthy tissues. The study indicates that Namodenoson promotes anti-inflammatory and anti-fibrotic effects, differentiating it from conventional chemotherapy. Currently, Namodenoson is undergoing multiple clinical trials, including a pivotal Phase III study for advanced liver cancer, showcasing its potential as a breakthrough cancer therapy. The drug has received Orphan Drug and Fast Track designations from regulatory agencies.
Read more →CANFDisappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat Gan, Israel
Can-Fite BioPharma announced a significant clinical development regarding its drug Namodenoson, which has led to the disappearance of episodes of decompensated liver cirrhosis in a patient under a compassionate use program. The patient experienced notable improvements in symptoms, including a decline in liver stiffness and reduced ascites. Given the current lack of approved treatments for advanced liver cirrhosis, Namodenoson represents a potential therapeutic option that could also provide patients with time until a liver transplant becomes available. The drug is also under evaluation in several clinical trials for different types of cancer.
Read more →CANF▲ +5.8%on this news
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
Can-Fite BioPharma Ltd. announced its participation in the BIO CEO & Investor Conference 2025 to present data on its lead anti-obesity drug, Namodenoson. The presentation is scheduled for February 10, 2025, in New York City, where the company's management will also engage with investors about its business strategy and clinical advancements. The company's pipeline includes advanced-stage candidates for oncology and metabolic diseases, demonstrating its commitment to addressing significant healthcare needs.
Read more →CANFUS Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Ga
Can-Fite BioPharma Ltd. announced that the US Patent Office granted a patent for its lead drug candidate, Namodenoson, for use as an anti-obesity treatment. The drug, which is already developed for conditions like MASH and various cancers, has shown promising weight loss results and an excellent safety profile in clinical trials. The patent, titled "An A3 adenosine receptor ligand for use for achieving a fat loss effect," will be valid until 2042. Can-Fite expresses optimism regarding the drug's potential impact in the growing obesity treatment market, projected to reach $60.5 billion by 2030.
Read more →CANFRecognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson Can-Fite's data will be presented at the 2025 ASCO Gastrointestinal Cancers Sympos
Can-Fite BioPharma announced that its anti-cancer drug Namodenoson will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. The drug demonstrates a liver protective effect and is currently in a Phase 3 trial for advanced liver cancer. Notably, a patient treated with Namodenoson remains cancer-free over eight years after treatment. The drug's unique properties may provide advantages over existing therapies that induce liver toxicity.
Read more →CANF▼ -20.1%on this news
Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug
Can-Fite BioPharma announced that a patient treated with Namodenoson for advanced liver cancer has achieved an 8-year survival with complete response. This patient, benefiting from a compassionate use program, has experienced the disappearance of ascites and normalization of liver function. The company is currently enrolling patients for a pivotal Phase III study, which has received regulatory agreement from the FDA and EMA. Namodenoson's promising profile positions it as a hopeful treatment option in an important and aggressive cancer market.
Read more →CANFCan-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Can-Fite BioPharma Ltd. announced that the first patient has been dosed in their Phase IIa clinical trial for advanced pancreatic adenocarcinoma, evaluating the safety and efficacy of their drug, Namodenoson. This trial aims to assess clinical activity and safety in patients whose disease has progressed despite prior treatment. The trial is set to enroll approximately 20 patients and is being conducted by notable oncologists in Israel and the US. Namodenoson has previously received Orphan Drug Designation, indicating its promising potential in the oncology space.
Read more →CANFCan-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Can-Fite BioPharma Ltd. announced that its lead drug candidate, Namodenoson, has received patent allowance in Australia for its use in treating obesity. This patent, which will be valid until 2040, covers methods of administering Namodenoson to obese patients. The drug has demonstrated efficacy in reducing body weight and enhancing factors related to fat production. Can-Fite is currently progressing with clinical trials for Namodenoson in multiple indications, including metabolic dysfunction-associated steatohepatitis and advanced liver cancer.
Read more →CANF▲ +6.3%on this news
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325
Can-Fite BioPharma announced that its veterinary partner Vetbiolix reported positive results from a multicenter clinical study of Piclidenoson for treating osteoarthritis in dogs. The study demonstrated significant improvement in clinical status and pain reduction in dogs treated with the drug. Vetbiolix has committed to a full license deal that could generate $325M for Can-Fite over the next decade, suggesting strong market potential for this treatment. The success of the study positions Piclidenoson favorably within the growing canine osteoarthritis market, projected to reach $3 billion by 2028.
Read more →CANF▲ +15.2%on this news
FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer
Can-Fite BioPharma has announced that its drug candidate Namodenoson has been granted Orphan Drug Designation by the FDA for treating pancreatic cancer. This designation may provide the company with seven years of market exclusivity and various regulatory benefits. Can-Fite is preparing for a Phase II study to investigate the safety and efficacy of Namodenoson in patients with advanced pancreatic cancer who have previously undergone treatment. The company aims to initiate this trial by the end of the year.
Read more →CANFProjected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis The agreement has been signed upon successful conclusion of a clin
Can-Fite BioPharma Ltd. has announced a development and commercialization agreement with Vetbiolix for its drug Piclidenoson, aimed at treating osteoarthritis in companion animals. Vetbiolix's option to license Piclidenoson followed a successful clinical study in dogs, indicating promising efficacy and safety. The estimated income of $325 million over the next decade reflects Can-Fite's potential royalty earnings upon regulatory approval. The veterinary market for osteoarthritis therapies is expected to grow significantly in the coming years.
Read more →CANFCan-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Can-Fite BioPharma Ltd. has received regulatory approval from the Israeli Ministry of Health to conduct a Phase IIa clinical trial for Namodenoson, targeting advanced pancreatic carcinoma. The study aims to evaluate the safety and clinical efficacy of the drug in patients whose disease has progressed following first-line therapy. With encouraging data from previous trials and a focus on a challenging oncology area, the company is optimistic about the potential outcomes of this trial.
Read more →CANFCan-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
Can-Fite BioPharma Ltd. announced its financial results and clinical progress for H1 2024, highlighting advancements in its drug candidates, Piclidenoson and Namodenoson. Positive interim results were reported from an osteoarthritis study in dogs, and the company continues to advance its Phase III clinical trials for liver cancer. Despite a decrease in revenue and a net loss, the company successfully exercised warrants generating $5 million in gross proceeds. Can-Fite remains focused on addressing multi-billion dollar markets with unmet medical needs.
Read more →CANF▲ +12.5%on this news
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
Can-Fite BioPharma Ltd. announced the immediate exercise of warrants to raise approximately $5.0 million. The company will issue new unregistered warrants as part of the agreement, which is expected to close around August 12, 2024. The proceeds from this exercise are earmarked for research and development, clinical trials, and general corporate purposes. This financing comes as Can-Fite continues to advance its pipeline of drugs targeting oncological and inflammatory diseases.
Read more →CANF▼ -13.2%on this news
Can-Fite Provides Namodenoson Patent Update Broad Protection of Namodenoson is expected till at least 2044
Can-Fite BioPharma Ltd. has announced an update on the patent status of its lead drug candidate, Namodenoson, which is expected to be protected until at least 2044. This protection covers methods of treating both advanced liver cancer and pancreatic cancer, alongside additional applications aimed at addressing liver conditions. The company is currently progressing through pivotal Phase III and Phase IIb clinical trials in collaboration with the FDA and EMA. Additionally, they have multiple approved patents across various international markets.
Read more →CANF▼ -13.2%on this news
Can-Fite Provides Namodenoson Patent Update
Can-Fite BioPharma Ltd. has provided an update on the intellectual property status of its lead drug candidate, Namodenoson, which is focused on treating advanced liver cancer, pancreatic cancer, and MASH. The company confirmed broad patent protection until at least 2044, covering both the use and manufacturing of the drug. Currently, Namodenoson is involved in a pivotal Phase III study for advanced liver cancer and a Phase IIb study for MASH with positive preliminary results. These advancements illustrate Can-Fite's commitment to expanding its product offerings in oncology and inflammatory diseases.
Read more →CANFCan-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
Can-Fite BioPharma has submitted a request to the FDA for Orphan Drug Designation for its drug candidate Namodenoson, aimed at treating pancreatic cancer. This designation can provide several advantages, including seven years of marketing exclusivity upon approval. The company plans to initiate a Phase IIa clinical study soon, which will assess the drug's safety and efficacy in patients with advanced pancreatic adenocarcinoma. Namodenoson has previously been granted Orphan Drug Status for other indications, demonstrating its potential in oncology treatments.
Read more →CANFImprovement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 1 st , 2024 -- Can-Fit
Can-Fite BioPharma announced a significant improvement in a patient with decompensated liver cirrhosis treated with Namodenoson at Soroka Medical Center. The patient, who had previously experienced critical health issues, showed positive changes in liver function tests and has not faced any decompensation events since treatment initiation. This development supports the drug's potential in addressing the challenges posed by liver cirrhosis, which currently lacks effective therapeutic options. Can-Fite aims to treat more patients under a compassionate use program and to further investigate the drug's efficacy in clinical studies.
Read more →CANFPositive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix The canine osteoarthritis market is projected to reach $3 billion by 2028 Ramat Gan, Israel
Can-Fite BioPharma announced positive results from a clinical study conducted by its partner Vetbiolix, which evaluated the efficacy of Piclidenoson for treating osteoarthritis in dogs. The study achieved its primary and secondary endpoints, showing notable improvements in dog mobility and pain levels. This successful outcome presents the opportunity for Vetbiolix to enter into a licensing agreement, impacting Can-Fite's potential revenues positively. The canine osteoarthritis market is projected to reach $3 billion by 2028, highlighting the significance of effective treatments in this space.
Read more →CANF▲ +5.3%on this news
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
Can-Fite BioPharma has revealed breakthrough findings concerning Namodenoson, a drug showing significant anti-cancer properties and protection in the liver through the signaling protein adiponectin. These findings will be presented at the IDDST-2024 congress in Shanghai. Namodenoson is currently undergoing pivotal Phase III trials for advanced liver cancer and has been granted Orphan Drug Designation and Fast Track Designation by regulatory bodies. The company is optimistic about its potential in treating various cancers and liver diseases.
Read more →CANFCan-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study Namodenoson showed efficacy in pre-clinical models via a definitive molecular mechanism of action
Can-Fite BioPharma has gained Institutional Review Board approval for its Phase IIa study on Namodenoson in pancreatic cancer patients. The open-label trial will evaluate the safety and efficacy of Namodenoson in patients whose cancer has progressed despite prior treatments. The study is based on pre-clinical results that indicate Namodenoson's potential effectiveness against pancreatic carcinoma. Can-Fite's Medical Director highlighted the positive outcomes observed in earlier studies as justification for this new trial.
Read more →CANFNOTICE OF 2024
Can-Fite BioPharma Ltd. will hold its 2024 Annual General Meeting of Shareholders on June 26, 2024, in Ramat Gan, Israel. The agenda includes the re-election of board members, the approval of options for directors, and an increase in authorized share capital. The meeting will also discuss the auditor's report and financial statements for the past year. Shareholders entitled to vote must be on record by May 29, 2024, and have the option to vote in person or through proxies, depending on their shareholding status.
Read more →CANFCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study Namodenoson granted Orphan Drug and Fast track status from the
Can-Fite BioPharma Ltd. has provided updates on its lead drug candidate, Namodenoson, for advanced liver cancer. The ongoing Phase 3 pivotal study has expanded to include 31 medical centers across Europe, Israel, and the U.S., with positive prior results indicating improved survival rates for patients. Namodenoson has been granted Orphan Drug and Fast Track statuses, which may expedite its development process. The trial aims to enroll 450 patients and evaluate the drug's efficacy and safety compared to a placebo.
Read more →CANFIndependent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases Ramat-Gan, Israel
Can-Fite BioPharma Ltd. announced that a scientific review published in the International Journal of Molecular Sciences highlights the therapeutic effects of its drugs piclidenoson and namodenoson on heart diseases. The review aggregates over 50 studies demonstrating the positive impact of these drugs on cardiac conditions, including protection against ischemic/injury and improved cardiac function. The company is also progressing with multiple clinical studies, including a Phase 3 trial for psoriasis and trials for liver cancer and pancreatic cancer. Can-Fite emphasizes the drugs' safety profile observed in previous clinical studies.
Read more →CANFCan-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study Can-Fite has received agreement
Can-Fite BioPharma recently held a conference attended by 75 oncologists and coordinators aimed at accelerating patient enrollment for its pivotal Phase 3 clinical study of Namodenoson, targeted at advanced liver cancer. The company has received agreements from the FDA and EMA, thus enhancing the study's credibility. Participants were educated on the drug's profile and study protocol, as well as patient data management during the trial. Namodenoson is recognized as a promising candidate for patients with hepatocellular carcinoma, addressing a substantial medical need in this area.
Read more →CANF▲ +6%on this newsshared move
Can-Fite: FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
Can-Fite BioPharma Ltd. announced that the FDA has granted Investigational New Drug (IND) clearance for Namodenoson, allowing the company to enroll patients in the U.S. for its ongoing Phase IIb clinical study targeting metabolic dysfunction-associated steatohepatitis (MASH). The study employs a double-blind, placebo-controlled design to evaluate the drug's efficacy. Namodenoson has previously shown positive results in a Phase IIa study, demonstrating the ability to reduce liver-related issues. Can-Fite aims to complete patient recruitment within the next few months.
Read more →CANFCan-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 Patent has already been issued in other major markets including the
Can-Fite BioPharma has received a Notice of Allowance from the European Patent Office for its CF602 drug candidate aimed at treating erectile dysfunction. This patent is already issued in major markets, including the U.S., and targets patients who cannot use current erectile dysfunction medications, particularly diabetics. Recent preclinical studies indicate that CF602 may improve erectile function significantly. The erectile dysfunction treatment market is anticipated to grow significantly in the coming years.
Read more →CANFLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Can-Fite BioPharma Ltd. has published a significant article in a leading scientific journal detailing a long-term complete response to its drug, Namodenoson, in a patient with advanced liver cancer. The patient, treated for over seven years, has exhibited improved liver function and quality of life. Can-Fite has gained approval for a pivotal Phase III clinical study to further evaluate Namodenoson as an effective treatment for Hepatocellular Carcinoma. The drug has Orphan Drug and Fast Track status, underscoring its potential in the market for liver cancer treatments.
Read more →CANFCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MA
Can-Fite BioPharma Ltd. has announced the publication of a scientific article that presents Namodenoson as a promising candidate for the treatment of advanced liver cancer and metabolic dysfunction-associated steatohepatitis (MASH). The article, authored by key opinion leader Dr. Ohad Etzion, details the drug's mechanism of action and its dual activity in cancer and liver disease. Namodenoson is currently undergoing evaluation in a pivotal Phase III trial approved by the FDA and EMA, alongside a Phase IIb study for MASH. The drug's favorable safety profile and positive clinical data further underscore its potential.
Read more →CANFCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa s
Can-Fite BioPharma has submitted an IND application to the FDA to enroll U.S. patients in its Phase IIb clinical trial for Namodenoson, targeting metabolic dysfunction-associated steatohepatitis (MASH). The drug has shown promising results in a Phase IIa study, reducing hepatic steatosis and inflammation. The ongoing trial is randomized and placebo-controlled, with an efficacy objective focused on histological endpoints. With MASH increasingly impacting U.S. adults, Can-Fite highlights the therapeutic potential of Namodenoson in addressing this growing health concern.
Read more →CANFCan-Fite Reports 2023 Financial Results and Clinical Update Ewopharma acquired marketing rights for namodenoson in the treatment of pancreatic carcinoma
Can-Fite BioPharma Ltd. reported its financial results for 2023 alongside key clinical updates on its drug candidates. Ewopharma has obtained marketing rights for Namodenoson, aimed at treating pancreatic carcinoma. The company has also reported positive outcomes from trials for both Namodenoson, which showed effectiveness for NASH, and Piclidenoson, which met primary endpoints in a Phase III psoriasis study. Financially, Can-Fite experienced a slight decline in revenues but also reduced its net loss, suggesting some operational efficiencies.
Read more →CANFNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Can-Fite BioPharma Ltd. announced that its VP of Business Development, Dr. Sari Fishman, will present data on the Namodenoson treatment for pancreatic and liver cancers at the BIO-Europe Spring 2024 conference in Barcelona. The drug is in various stages of clinical trials, with interest from partners across multiple regions, including Eastern Europe and Asia. Can-Fite’s strategic approach focuses on building partnerships with companies for market-specific distribution and regulatory approval. The conference provides a platform for Can-Fite to showcase its developments to leading pharmaceutical companies.
Read more →CANFCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada Patent has already been issued in other major markets including the U.S., EU, Japan and China
Can-Fite BioPharma has announced the receipt of a Notice of Allowance from the Canadian Intellectual Property Office for a patent application related to the treatment of non-alcoholic steatohepatitis (NASH) using Namodenoson. The company has reported positive results from earlier Phase IIa trials and is currently preparing to begin a Phase IIb study involving 140 patients. The growing market for NASH treatments is expected to create significant opportunities for Can-Fite as it advances its drug development efforts.
Read more →CANFCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Can-Fite BioPharma Ltd. has expanded its existing out-licensing agreement with Ewopharma AG to include a pancreatic cancer indication for its drug Namodenoson. This move follows an earlier agreement covering psoriasis and hepatocellular carcinoma treatments. The deal allows Can-Fite to benefit from upfront and milestone payments, as well as royalties on sales when the drug is approved. The company aims to capitalize on the lack of effective treatments for this indication within the targeted markets.
Read more →CANF▲ +7.1%on this newsshared move
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderat
Can-Fite BioPharma Ltd. announced that a top scientific journal has published positive data from the COMFORT-1 Phase III psoriasis study of Piclidenoson, an oral drug aimed at treating moderate to severe plaque psoriasis. The study met its primary endpoint, showing a significant improvement in psoriasis severity among treated patients. With favorable safety and efficacy results, Can-Fite is optimistic about further evaluations in the ongoing COMFORT-2 trial approved by regulatory authorities.
Read more →CANFThe Anti-Obesity Effect of Can-Fite's Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies Robust support for Namodenoson's potential development as an anti-obesity drug, a projected $100 billion
Can-Fite BioPharma reported new data on Namodenoson's mechanism of action, indicating its potential as an anti-obesity treatment. In both preclinical studies and a Phase IIa trial, Namodenoson effectively reduced body weight and increased the level of adiponectin, a protein involved in fat metabolism. The anti-obesity market is projected to grow to $100 billion by 2030, making this development timely. The drug is characterized by a good safety profile, further enhancing its prospects for market entry.
Read more →CANFCan-Fite Received FDA Positive Response to Psoriasis Pediatric Plan FDA encouraged the Company to accelerate enrollment of adolescent patients due to Piclidenoson's good safety profile There is an unmet need for safe, co
Can-Fite BioPharma Ltd. announced that it received a positive response from the FDA regarding its Pediatric Study Plan for Piclidenoson, aimed at treating psoriasis in children. The company's plan allows enrollment of pediatric patients in upcoming Phase 3 clinical trials, targeting registration with the FDA and EMA. Can-Fite believes that including children in the studies is crucial for expanding the drug's market potential given the current lack of effective safe treatments for pediatric psoriasis. The favorable safety profile of Piclidenoson positions it as a promising option for this condition.
Read more →CANFCan-Fite's Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development Study will aim to enroll about 20 patients to establish safety and clinical activity
Can-Fite BioPharma Ltd. is progressing with its Phase IIa clinical study of Namodenoson, aimed at treating advanced pancreatic adenocarcinoma. The study plans to enroll approximately 20 patients whose cancer has either progressed after first-line therapy or who declined standard treatment. Designed as an open-label trial, it will examine the safety, clinical activity, and pharmacokinetics of Namodenoson. This follows positive results from prior studies and recognitions from various scientific forums.
Read more →CANFCan-Fite Reports Third Quarter 2023 Financial Results and Clinical Update Advanced liver cancer patient in prior Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson
Can-Fite BioPharma reported its third quarter 2023 financial results, highlighting a noteworthy milestone where a patient treated with Namodenoson has remained cancer-free for 6.9 years. The company continues its pivotal Phase III study for this drug in liver cancer treatment. Additionally, Can-Fite is expanding its pipeline with a new indication for Piclidenoson in treating Lowe Syndrome, a rare genetic disease. The company has also received accolades from notable cancer associations, affirming the efficacy of its drug candidates.
Read more →CANFCan-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
Can-Fite BioPharma announced a significant milestone with a patient in its Phase II Liver Cancer Study achieving a complete response to treatment with namodenoson, resulting in an overall survival duration of 6.9 years. The company has also gained regulatory approval from both the FDA and EMA to advance to a pivotal Phase III clinical trial, which is currently enrolling patients across multiple regions. This trial aims to evaluate the efficacy of namodenoson for patients with advanced liver cancer, designated as Child Pugh B. Should interim analysis results prove favorable, the company hopes to expedite the drug's approval process for broader use in treating this difficult disease.
Read more →CANF▲ +6.7%on this news· ran to +19% by day 3shared move
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
Can-Fite BioPharma Ltd. announced the exercise of outstanding warrants, generating approximately $3.0 million in gross proceeds. This exercise comes under a definitive agreement which allows for the purchase of up to 1,963,637 American Depositary Shares at a reduced exercise price. The funds are intended to support the company's research and clinical trials, enhancing its pipeline of drug candidates. Additionally, new warrants for further capital raise were also issued in the deal.
Read more →CANFCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track Company management updates about ongoing activities and progress
Can-Fite BioPharma Ltd. has updated its stakeholders that all clinical programs and business development activities are on track. The company's pipeline includes pivotal Phase III studies in advanced liver cancer and psoriasis, with a strong focus on international collaboration and partnerships. Management highlighted increased interest in its drug candidates, Namodenoson and Piclidenoson, positioning them for potential future deals. Can-Fite is also leveraging AI and ML to enhance drug development, particularly in the rare genetic diseases market.
Read more →CANFCan Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action These data support namodenoson as a leading drug candidate to treat p
Can-Fite BioPharma has announced that its drug Namodenoson inhibits pancreatic carcinoma, with findings published in the journal Biomolecules. The research details significant growth inhibition through the de-regulation of key signaling pathways and promotes apoptosis in cancer cells, showcasing its potential as a leading treatment option. Can-Fite is preparing to initiate a Phase II trial for patients with advanced pancreatic carcinoma following previous treatment failures, and Namodenoson has already gained approval for pivotal Phase III studies by regulatory agencies. The drug also has an encouraging safety profile, which is essential given the resistance of pancreatic carcinoma to current chemotherapy treatments.
Read more →CANFCan-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs Can-Fite signed an agreement with Collaborations Pharmaceuticals, a leading expert in Artificial Intelligence and Machine Learning
Can-Fite BioPharma Ltd. has announced a collaboration with Collaborations Pharmaceuticals, Inc. to use artificial intelligence and machine learning in developing anti-cancer drugs. This partnership aims to enhance the efficiency and cost-effectiveness of bringing new treatments to market, specifically focusing on A3 adenosine receptor drug agonists. The collaboration will see CPI leveraging its AI technology to design new drug molecules, while Can-Fite will conduct biological testing of these new candidates. This strategic move highlights Can-Fite's commitment to innovating cancer treatment solutions.
Read more →CANF▼ -11.5%on this news
Can Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
Can-Fite BioPharma Ltd. is set to present its novel treatment for Lowe Syndrome at the BioJapan Conference, aiming to engage with Japanese companies focused on orphan drugs. The company recently signed a co-development agreement with Fondazione Telethon, based on promising pre-clinical efficacy results for Piclidenoson, its treatment candidate. This marks Can-Fite's first foray into treating rare genetic diseases, reflecting increased interest from Japanese pharmaceutical firms in their innovative solutions.
Read more →CANFCan-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) Namodenoson robustly inhibits pancreatic carcinoma growth in
Can-Fite BioPharma announced that its study on Namodenoson, a treatment for pancreatic carcinoma, has been accepted for presentation at the AACR Special Conference. The study shows significant inhibition of pancreatic cancer growth through the de-regulation of essential signaling pathways. Namodenoson is being prepared for a Phase II trial targeting pancreatic carcinoma patients with limited treatment options. The recognition from the AACR highlights the potential impact of these findings in the oncology field.
Read more →CANFSmall Molecules for Big Clinical Needs NYSE American:CANF | September 2023 Investor Presentation TM Forward Looking Statement 2 This presentation contains forward - looking statements, about Can - Fite's expectations, be
Can-Fite Biopharma's recent investor presentation highlighted its drug candidates aimed at oncological and inflammatory diseases, particularly emphasizing advancements with Piclidenoson for psoriasis and Namodenoson for liver cancer. The company has established a strong clinical proof of concept with excellent safety profiles across multiple trials. However, it also faces significant challenges, including financial losses, capital needs, and the uncertainty of regulatory approvals. Additionally, ongoing geopolitical tensions may affect future operations.
Read more →CANFCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome Can-Fite Signed agreement wit
Can-Fite BioPharma has announced its entry into the rare genetic disease arena by developing its lead candidate, Piclidenoson, for Lowe Syndrome. This decision is based on promising pre-clinical findings from researchers at the University of Naples and Fondazione Telethon, which indicate Piclidenoson may significantly reduce protein loss in affected mice. The collaboration with Fondazione Telethon aims to expedite the drug’s development, tapping into an estimated $100 million U.S. market. Additionally, Piclidenoson may qualify for Orphan Drug Designation to support accelerated review and market exclusivity.
Read more →CANFCan-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis FDA encouraged the Company to enroll adolescent patients due to Piclidenoson's good safety
Can-Fite BioPharma Ltd. submitted a pediatric study plan to the FDA for the treatment of adolescents with psoriasis using Piclidenoson. This initiative aims to include adolescents in two upcoming Phase 3 pivotal clinical trials, addressing a significant market need for safe and effective psoriasis treatments. The FDA's encouragement reflects the drug's favorable safety and efficacy profile, potentially broadening its market launch opportunities. Can-Fite seeks to position Piclidenoson as a leading therapeutic option for this challenging disease affecting millions of adolescents worldwide.
Read more →CANFCan-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation Can-Fite's novel approach for the treatment of advanced liver cancer will be presented
Can-Fite BioPharma announced that its abstract on Namodenoson for advanced liver cancer won the Breakthrough Abstract Award from the ASCO Conquer Cancer Foundation. The drug is currently undergoing pivotal Phase 3 trials and has previously shown effectiveness in a Phase 2b trial. The recognition highlights the potential of Namodenoson in the oncology field, particularly for patients who have not responded to existing treatments. Can-Fite is keen to present its findings at the upcoming ASCO Breakthrough Meeting in Japan.
Read more →CANFCan-Fite Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan FDA encouraged the Company to enroll adolescent patients due to the strong safety profile of the drug demonstrated over the development h
Can-Fite BioPharma Ltd. has received approval from the U.S. FDA for the registration plan of Piclidenoson, a treatment for moderate to severe plaque psoriasis. The FDA acknowledged the drug's positive safety profile and suggested including adolescent patients in the upcoming Phase 3 trials. Can-Fite plans to conduct two Phase 3 studies simultaneously to meet the requirements of both the FDA and the European Medicines Agency (EMA). The inclusion of adolescents is expected to enhance the market potential for the drug, which addresses a significant treatment gap for this demographic.
Read more →CANFNOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2023 Annual General Meeting of Shareholders will be held o
Can-Fite BioPharma Ltd. is set to hold its 2023 Annual General Meeting of Shareholders on July 31, 2023, in Petach Tikva, Israel. The agenda includes re-elections for board directors, approval of options grants, and amendments to terms of employment for key executives. Shareholders and holders of American Depositary Shares are entitled to vote, and the company encourages participation through proxies if they cannot attend. The meeting will also discuss the auditor's report for the previous fiscal year.
Read more →CANF▲ +11.4%on this news· ran to +22% by day 3
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson Namodenoson's robust effect reached 90% inhibition of pancreatic cancer growth in pre-clinical studies
Can-Fite BioPharma Ltd. announced plans to submit an Investigational New Drug application to the FDA for Namodenoson, aimed at treating pancreatic cancer. Pre-clinical studies indicated promising results with a 90% growth inhibition of pancreatic carcinoma cells. A Phase 2 exploratory trial will assess the drug's safety and efficacy in treating patients who have undergone prior systemic therapy. The company's progress indicates a growing pipeline in oncology, with Namodenoson also involved in multiple other clinical trials for different cancer indications.
Read more →CANFCan-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
Can-Fite BioPharma Ltd. has reported its financial results for the first quarter of 2023, indicating ongoing developments in its clinical pipeline. The company is advancing pivotal studies for Namodenoson in treating liver cancer and is preparing a Phase 2 trial for pancreatic cancer. Additionally, it received a positive opinion from the EMA for a Phase 3 psoriasis trial. Despite a slight increase in net loss, Can-Fite continues to focus on its candidates with potential for addressing significant health issues in cancer and liver diseases.
Read more →CANF▲ +10%on this news· ran to +25% by day 3shared move
Can-Fite: Namodenoson's Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO) Abstract published online in the Journal of Clinical Oncology supplement of the 2023 A
Can-Fite BioPharma announced that its preclinical study on Namodenoson, an investigational drug for pancreatic carcinoma, was published in the Journal of Clinical Oncology as part of the 2023 ASCO Annual Meeting Proceedings. The study demonstrated a significant inhibition of pancreatic cancer cell growth, both with Namodenoson alone and in combination with gemcitabine. Can-Fite plans to launch a Phase 2a exploratory trial to evaluate Namodenoson's efficacy and safety in patients with prior systemic therapy. These findings build on prior positive outcomes of Namodenoson in other oncology applications.
Read more →CANFCan-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients Exploratory, small, open-label study aims to assess potential efficacy of Namodenoson following strong preclinical results in
Can-Fite BioPharma Ltd. announced the initiation of an exploratory Phase 2 trial to evaluate Namodenoson for pancreatic cancer patients following prior systemic treatments. The trial, led by a key oncology opinion leader, aims to assess efficacy and safety, with a focus on various endpoints like overall survival and progression-free survival. Can-Fite highlights Namodenoson's promising results from preclinical studies, indicating its potential effectiveness in a disease area that requires better treatment options.
Read more →CANF▲ +14.3%on this news
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists The anti-cancer effect in pancreatic carcinoma is mediated via a key signal transduction pathway According t
Can-Fite BioPharma has identified the molecular mechanism of action of its drug Namodenoson, which shows significant anti-cancer effects in pancreatic carcinoma by targeting the Wnt signaling pathway. This discovery came from pre-clinical studies involving pancreatic cancer patient cells and supports ongoing research into the drug's efficacy. Namodenoson is currently undergoing a Phase III study for liver cancer and has previously demonstrated success in treating liver cancer patients. The findings enhance the prospects for Namodenoson and inform future trial design.
Read more →CANFCan-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization Dr. Pnina Fishman appointed Executive Chairman of the Board Mot ti Farbstein appointed Chief Executive Officer in addi
Can-Fite BioPharma has announced a new management structure to support the advancement of its clinical pipeline towards commercialization. Dr. Pnina Fishman has been appointed as Executive Chairman of the Board while continuing her role as Chief Scientific Officer. Motti Farbstein will take over as CEO, maintaining his role as Chief Financial Officer. The company focuses on pivotal Phase III trials for treatments in psoriasis and liver cancer, with plans for future commercialization milestones.
Read more →CANFCan-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment The Pivotal Study is Aimed to Support a Marketing Authorization Application
Can-Fite BioPharma has received a positive opinion from the European Medicines Agency (EMA) regarding its pivotal Phase III clinical trial for Piclidenoson, aimed at treating moderate to severe psoriasis. The trial will be double-blind, placebo-controlled, and randomized, focusing on demonstrating the drug's safety and efficacy. Can-Fite's previous Phase III results for the drug showed significant improvement in psoriasis patients compared to placebo, with a noteworthy safety profile. The company is also preparing submissions to the US FDA for further regulatory approval.
Read more →CANF▲ +5.7%on this news
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
Can-Fite BioPharma Ltd. reported its 2022 financial results, highlighting key developments in its clinical pipeline. The company achieved significant progress in its Phase III trial for Piclidenoson in psoriasis and submitted a market registration plan to the EMA. Additionally, positive preclinical results were reported for Namodenoson against pancreatic cancer, and a patent was granted for treating liver fibrosis. Despite a minor decrease in revenue, the net loss showed improvement compared to the previous year.
Read more →CANFCan-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting Liver organ shortage puts patients at risk of death from decompensated cirrhosis with no treatment options availab
Can-Fite BioPharma has announced the treatment of patients with decompensated cirrhosis using Namodenoson at Soroka Medical Center under compassionate use. This advanced form of cirrhosis currently has no therapeutic options aside from liver transplantation, highlighting the critical need for new treatments. Namodenoson is also being tested in Phase III and Phase IIb studies for advanced liver cancer and NASH, respectively. The decision reflects the urgency of addressing the shortage of liver donors and the high demand for effective therapies in this patient population.
Read more →CANF▼ -6.4%on this news
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo Namodenoson is being evaluated in a pivotal Phase II
Can-Fite BioPharma has published promising results about its drug, Namodenoson, for treating advanced liver cancer. The peer-reviewed study indicates that patients treated with Namodenoson experienced a 12-month survival rate of 44%, significantly higher than the 18% observed in the placebo group. The drug is currently undergoing a pivotal Phase III study, having gained approval from the FDA and EMA, and has demonstrated a favorable safety profile in previous trials. The ongoing evaluation aims to confirm its efficacy in a broader patient population.
Read more →CANF▼ -6.3%on this news· ran to -22% by day 1
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies-A Patent Has Been Filed Data show significant anti-cancer effect in pancreatic carcinoma as a monotherapy and an additive effect when
Can-Fite BioPharma announced that their anti-cancer drug Namodenoson significantly inhibits the growth of pancreatic carcinoma in preclinical studies. The drug demonstrates both stand-alone effectiveness and an additive effect when combined with gemcitabine chemotherapy. Following promising results in liver cancer treatments, Can-Fite has filed a patent application for Namodenoson's use in pancreatic cancer. The findings underscore a potential pathway for developing safe and effective treatments for pancreatic cancer, which has a high global mortality rate.
Read more →CANFNOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 21, 2023 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that Special General Meeting of Sha
Can-Fite BioPharma Ltd. has announced a Special General Meeting to be held on February 21, 2023, at its offices in Israel. The key agenda items include the approval of a renewed Compensation Policy for three years and the cancellation of the par value of ordinary shares. Only shareholders and ADS holders as of January 19, 2023, are eligible to vote. The company's Board of Directors recommends voting in favor of the proposals.
Read more →CANF▼ -16.1%on this newsshared move
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
Can-Fite BioPharma Ltd. has announced a concurrent registered direct offering and private placement, aiming to raise $7.5 million by selling a total of 1,363,637 American Depositary Shares (ADSs) at a price of $5.50 each. The gross proceeds will be allocated to funding research and development activities, as well as for general corporate purposes. The offerings are expected to close by January 13, 2023, with the company also amending the exercise prices for previously issued warrants.
Read more →CANFCan-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow As an oral treatment with an excellent safety and efficacy profile, Picliden
Can-Fite BioPharma Ltd. has announced the submission of a market registration plan for its lead drug candidate, Piclidenoson, to the European Medicines Agency for the treatment of moderate to severe psoriasis, with an FDA submission to follow. The recent Phase III COMFORT study showed significant efficacy and an excellent safety profile, suggesting Piclidenoson's potential to compete in the $26 billion psoriasis treatment market. The submission includes critical clinical trial data and a request for registration advice as the company aims for marketing approval and further pivotal studies.
Read more →CANF▼ -5.7%on this news
Can-Fite Announces ADS Ratio Change
Can-Fite Announces ADS Ratio Change PETACH TIKVA, Israel, December 30, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, ann
Read more →CANF▲ +8.2%on this newsshared move
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer Results to be shared at Biotech Showcase during JP Morgan conference week in San Francisco and at BI0-CEO in New Yo
Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer PETACH TIKVA, Israel, December 28, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drug
Read more →CANFCan-Fite's Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets' Osteoarthritis The canine osteoarthritis market is projected to reach $3 billion by 2028
Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets' Osteoarthritis The canine osteoarthritis market is projected to reach $3 billion by 2028 PETACH TIKVA, Israel, December 8, 2022 -- Can-Fite BioPharma Ltd. (
Read more →CANFCan-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, November 25, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addres
Read more →CANFCan-Fite: Positive New Data from it's Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston The Summit will host industry drug development experts, all in the dermatology arena, who wil
Can-Fite: Positive New Data from it's Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston PETACH TIKVA, Israel, November 2, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of
Read more →CANF▲ +10%on this news
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated with Namodenoson will be Presented at the AASLD Liver Meeting Namodenoson is now in a global pivotal Phase III study for advanced liver cance
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated with Namodenoson will be Presented at the AASLD Liver Meeting Namodenoson is now in a global pivotal Phase III study for advanced liver cancer PETACH TIKVA, Israel, October 25, 2022 -- Can-Fite Bi
Read more →CANFCan-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology Dr. Papp: "The safety results on Piclidenoson and its progressive e
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology PETACH TIKVA, Israel, September 12, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology comp
Read more →CANF▲ +7.1%on this newsshared move
Can-Fite's Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania Namodenoson induced a complete response with disappearance of all metastases in a patient who will now con
Can-Fite's Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania PETACH TIKVA, Israel, August 23, 2022-- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small mo
Read more →CANFCan-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31 st European Academy of Dermatology and Venerology Congress Presentation by study's co-author Dr. Kim Papp, a Key Opinion Leader who has complet
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress PETACH TIKVA, Israel, August 22, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipel
Read more →CANFCan-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix Safety study successfully completed; efficacy trial to commence and financially covered by Vetbiolix
Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix TIKVA, Israel, August 17, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule
Read more →CANFNOTICE OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 29, 2022 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2022 Annual General Meeting of Shareholders will be held
2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 29, 2022 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2022 Annual General Meeting of Shareholders will be held on Monday, August 29, 2022, at 3:00 p.m. Israel time at our offic
Read more →CANF▲ +12.2%on this news
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis Further analysis of Phase III COMFORT TM data show Piclidenoson's superior safety profile and higher
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis Further analysis of Phase III COMFORTTM data show Piclidenoson's superior safety profile and higher patient compliance compared to Otezla PETACH TIKVA, Israe
Read more →CANF▲ +15.6%on this news
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT TM Study in Moderate to Severe Psoriasis Phase III COMFORT TM study met its primary endpoint with statistically significant improvement and
Announces Positive Top-Line Results from Piclidenoson Phase III COMFORTTM Study in Moderate to Severe Psoriasis PETACH TIKVA, Israel, June 29, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small
Read more →CANFCan-Fite's CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia CF602's unique mechanism of action enables potential treatment of diabetic patients and m
Can-Fite's CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia PETACH TIKVA, Israel, June 24, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of
Read more →CANFCan-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal Data suggest Piclidenoson and Namodenoson could potentially be the first A3AR agonists to achieve FDA approval
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal PETACH TIKVA, Israel, June 9, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small mole
Read more →CANFCan-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, May 26, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inf
Read more →CANFCan-Fite Granted Key NASH Patent in Israel Phase IIb NASH study is currently enrolling patients; Phase IIa met endpoints including reduced liver fat content
Can-Fite Granted Key NASH Patent in Phase IIb NASH study is currently enrolling patients; Phase IIa met endpoints including reduced liver fat content PETACH TIKVA, Israel, May 16, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company adva
Read more →CANFCan-Fite's CEO to Present Namodenoson's Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit Namodenoson induced complete response and cleared all cancer lesions in adv
Can-Fite's CEO to Present Namodenoson's Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit PETACH TIKVA, Israel, May 2, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a
Read more →CANFCan-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug Topical psoriasis treatments account for
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug PETACH TIKVA, Israel, April 5, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI),
Read more →CANFCan-Fite Reports 2021 Financial Results & Provides Clinical Update Cash balance of $18.9 million as of
Can-Fite Reports 2021 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, March 24, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, c
Read more →CANFCan-Fite: Namodenoson's Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office Broad patent addresses markets for the treatment of all advanced liver fibrosis indications
Can-Fite: Namodenoson's Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office Broad patent addresses markets for the treatment of all advanced liver fibrosis indications PETACH TIKVA, Israel, March 14, 2022 -- Can-Fite BioPharma Ltd. (NYSE America
Read more →CANFCan-Fite's Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv Can-Fite will conduct 1x1 meetings with companies in the cannabis field regarding
Can-Fite's Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv Can-Fite will conduct 1x1 meetings with companies in the cannabis field regarding potential collaboration PETACH TIKVA, Israel, March 11,
Read more →CANFCan-Fite's Phase III Psoriasis Study Data Expected Q2 2022
Can-Fite's Phase III Psoriasis Study Data Expected Q2 2022 PETACH TIKVA, Israel, March 8, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and
Read more →CANFCan Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson Namodenoson met primary endpoint in Phase IIa NASH study by reducing liver fat, inhibiting fibrosis, and demonstrating anti-infl
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson Namodenoson met primary endpoint in Phase IIa NASH study by reducing liver fat, inhibiting fibrosis, and demonstrating anti-inflammatory effect PETACH TIKVA, Israel, January 31, 2022 --
Read more →CANFPrior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel, January 13, 2022 -- Can-Fite BioPharma Ltd
Read more →CANFCan-Fite Issues Letter to Shareholders Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer
Can-Fite Issues Letter to Shareholders PETACH TIKVA, Israel, January 5, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, to
Read more →CANFFollowing Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors Namodenoson Headed into Pivotal Phase III Liver C
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel, December 29, 2021 -- C
Read more →CANFCan-Fite Announces Exercise of Warrants for Cash Proceeds of $10 Million
PETACH TIKVA, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the agreement
Read more →CANFLiver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Pivotal Phase 3 Study to Commence Q1 2022
Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Pivotal Phase 3 Study to Commence PETACH TIKVA, Israel, December 20, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechn
Read more →CANFCan-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022 Piclidenoson is seeking to address $11 billion psoriasis market in need of treatments with mini
Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022 Piclidenoson is seeking to address $11 billion psoriasis market in need of treatments with minimal-to-no side effects PETACH TIKVA, Israel, December 7
Read more →CANFCan-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update
Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, November 26, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addres
Read more →CANFCan-Fite's Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis Study conducted and costs covered by Vetbiolix, Can-Fite's development and commercialization partner for the veterinary market C
Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis TIKVA, Israel, November 23, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm
Read more →CANFCan-Fite's NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico Can-Fite continues to build IP for its NASH drug candidate Namodenoson with patents granted and allowed in 37 countries
NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico continues to build IP for its NASH drug candidate Namodenoson with patents granted and allowed in 37 countries TIKVA, Israel, October 28, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biote
Read more →CANFPositive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal PETACH TIKVA, Israel, October 21, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecu
Read more →CANFCan-Fite Completes Patient Enrollment in Phase III Psoriasis Study Positive interim analysis data was released in October 2020 based on results from 200 patients Topline results expected Q1 2022
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study PETACH TIKVA, Israel, September 2, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory,
Read more →CANFCan-Fite Announces $10.0 Million Registered Direct Offering
Can-Fite Announces $10.0 Million Registered PETACH TIKVA, Israel, August 12, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR
Read more →CANFYossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board Yossi Borenstein to contribute his skills acquired through his 35 years of experience in the life science industry
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the TIKVA, Israel, August 5, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 a
Read more →CANFCan-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study FDA Granted Namodenoson Orphan Drug and Fast Track Status
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study FDA Granted Namodenoson Orphan Drug and Fast Track Status PETACH TIKVA, Israel, July 8, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of propr
Read more →CANFCan-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets All pre-clinical, clinical, and regulatory development work to be conducted a
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets Can-Fite PETACH TIKVA, Israel, June 28, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company ad
Read more →CANFNOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 29, 2021 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be
SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 29, 2021 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be held on Thursday, July 29, 2021, at 3:00 p.m. Israel time at our
Read more →CANFCan-Fite Receives Notice of Patent Allowance in China for NASH Treatment Namodenoson is out-licensed in China for NASH, projected to become $6.4 billion market by 2027
Receives Notice of Patent Allowance in China for NASH Treatment is out-licensed in China for NASH, projected to become $6.4 billion market by 2027 TIKVA, Israel, June 16, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipe
Read more →CANFCan-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson A prior Phase IIa clinical trial has been successfully concluded and met study end points
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson A prior Phase IIa clinical trial has been successfully concluded and met study end points PETACH TIKVA, Israel, June 2, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechn
Read more →CANFNOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 7, 2021 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2021 Annual General Meeting of Shareholders will be held on
2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 7, 2021 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2021 Annual General Meeting of Shareholders will be held on Monday, June 7, 2021, at 3:00 p.m. Israel time at our offices, 10
Read more →CANFCan-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update Can-Fite
Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update Can-Fite PETACH TIKVA, Israel, May 27, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that add
Read more →CANFCan-Fite's Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Prompted by positive interim analysis data Can-Fite accelerates patient enrollment Can-Fite
Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Prompted by positive interim analysis data Can-Fite accelerates patient enrollment Can-Fite PETACH TIKVA, Israel, April 29, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI),
Read more →CANFNOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 31, 2021 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2021 Annual General Meeting of Shareholders will be held on
2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 31, 2021 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2021 Annual General Meeting of Shareholders will be held on Monday, May 31, 2021, at 3:00 p.m. Israel time at our offices, 10
Read more →CANFCan-Fite Expands its Phase II COVID-19 Study to Europe The Phase II Study is under FDA Protocol and data are expected Q4 2021
Can-Fite Expands its Phase II COVID-19 The Phase II Study is under FDA Protocol and data are expected Q4 2021 PETACH TIKVA, Israel, April 22, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small m
Read more →CANFCan-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates Piclidenoson in Phase III for Psoriasis & Namodenoson to Enter Pivotal Phase III for Liver Cancer
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates Piclidenoson in Phase III for Psoriasis & Namodenoson to Enter Pivotal Phase III for Liver Cancer PETACH TIKVA, Israel, April 20, 2021 -- Can-Fite BioPharma Lt
Read more →CANFCan-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies Patent applications filed to protect discovery of cannabinoid-based therapies where the A3AR target is overexpressed including liver cancer
Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies Patent applications filed to protect discovery of cannabinoid-based therapies where the A3AR target is overexpressed including liver cancer PETACH TIKVA, Israel, April 5, 2021 -- Can-Fite BioPhar
Read more →CANFCan-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million In addition, to date ~$20 million in non-dilutive upfront payment received
Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million In addition, to date ~$20 million in non-dilutive upfront payment received PETACH TIKVA, Israel, March 30, 2021 -- Can-Fite BioPharma Ltd. (NYSE American:
Read more →CANFCan-Fite Reports 2020 Financial Results & Provides Clinical Development Update $5M cash infusion received in warrant exercises and upfront money from a licensing deal "2020 was a pivotal year for Can-Fite as we demonstra
Reports 2020 Financial Results & Provides Clinical Development Update cash infusion received in warrant exercises and upfront money from a licensing deal was a pivotal year for Can-Fite as we demonstrated a robust clinical proof of concept for both Piclidenoson and Namodenoson,
Read more →CANFCan-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model Issued Patents in major markets including the U.S., Australia, China, and Japan
Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model PETACH TIKVA, Israel, March 18, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs
Read more →CANFCan-Fite Signs $42.7 M illion Out-Licensing Deal with Ewopharma Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE) $2.25 million upfront payment with an additional $40.45 million for r
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma TIKVA, Israel, March16, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and live
Read more →CANFCan-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol Piclidenoson's robust anti-inflammatory effect has the potential to treat COVID-19 and its mutations
Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol Piclidenoson's robust anti-inflammatory effect has the potential to treat COVID-19 and its mutations PETACH TIKVA, Israel, March 5, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI),
Read more →CANFNew Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson Overall survival of nearly 4 years in two patients with disappearance of ascites, normal liver function, and good quality of life
New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson Overall survival of nearly 4 years in two patients with disappearance of ascites, normal liver function, and good quality of life PETACH TIKVA, Israel, February 22, 2021 -- Can-Fite BioP
Read more →CANFCan-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies T3/C15 enriched cannabis fraction inhibits liver fibrosis Findings add to Can-Fite's expertise and assets in the treatment of l
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies PETACH TIKVA, Israel, February 1, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs t
Read more →CANFCan-Fite's NASH Indication Highlighted in Webinar by KOL Dr. Harrison: "Namodenoson May Have Big Impact on NASH"
Can-Fite's NASH Indication Highlighted in Webinar by KOL Dr. Harrison: "Namodenoson May Have Big Impact on NASH" PETACH TIKVA, Israel, January 28, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary sma
Read more →CANFCan-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal-Cancers Significant 12-month overall survival benefit in the CPB7 population and 2 patients are still under treatment for more tha
Announces Publication of Namodenoson Liver Cancer Study in Peer TIKVA, Israel, January 8, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and li
Read more →CANFCan-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs - State-of-the-art in house labs leveraged for cost and time ef
Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs PETACH TIKVA, Israel, December 15, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology co
Read more →CANFCan-Fite Reports on Progress with its Namodenoson NASH Program Top NASH U.S. Key Opinion Leaders advise on the design of a Phase IIb protocol Manufacturing of Namodenoson for the Phase IIb study is completed NASH patents
Can-Fite Reports on Progress with its Namodenoson NASH Program PETACH TIKVA, Israel, December 14, 2020 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, canc
Read more →CANFCan-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update Company to host conference call at 9:15 a.m. ET Monday
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update Company to host conference call at 9:15 a.m. ET Monday, November 30, 2020 PETACH TIKVA, Israel, November 30, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology co
Read more →CANFCan-Fite's Namodenoson Abstract Selected as Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD)
Can-Fite's Namodenoson Abstract Selected as Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD) PETACH TIKVA, Israel, November 24, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advan
Read more →CANFCan-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference Dr. Safadi, the study's Principal Investigator: "Namodenoson's v
Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference Dr. Safadi, the study's Principal Investigator: "Namodenoson's very impressive study data may result in a promising drug
Read more →CANFNOTICE OF 2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 2, 2020 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2020 Annual General Meeting of Shareholders will be hel
2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 2, 2020 To the shareholders of Can-Fite BioPharma Notice is hereby given that the 2020 Annual General Meeting of Shareholders will be held on Wednesday, December 2, 2020, at 12:00 p.m. Israel time at our offi
Read more →CANFCan-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 Key Opinion Leader in the Treatment of Psoriasis to Join the Presentation and Q&A PETACH TIKVA, Israel, October 13, 2020 -- Can-Fite BioPh
Read more →CANFCan-Fite Announces Positive Phase III Psoriasis Interim Data Analysis Independent Data Monitoring Committee (IDMC) conducted a pre-planned interim analysis of the Company's Phase III Comfort trial of Piclidenoson for the
Announces Positive Phase III Psoriasis Interim Data Analysis PETACH TIKVA, Israel, October 06, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer
Read more →CANFCan-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson's Treatment of NASH at American Association for the Study of Liver Diseases Conference Principal Investigator Prof. Rifaat Safadi to present Nam
Selected to Deliver Late-Breaking Oral Presentation on Namodenoson's Treatment of NASH at American Association for the Study of Liver Diseases Conference Investigator Prof. Rifaat Safadi to present Namodenoson's Phase II results at highly prestigious scientific conference for
Read more →CANFFDA Clears Can-Fite to Commence Phase II COVID-19 Study Piclidenoson has a robust anti-inflammatory effect with an excellent safety profile
FDA Clears Can-Fite to Commence Phase II COVID-19 Study Piclidenoson has a robust anti-inflammatory effect with an excellent safety profile PETACH TIKVA, Israel, August 31, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a
Read more →CANFCan-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH Marks Can-Fite's 3 rd major patent for treatment of NASH; patents have also been received in the U.S. an
Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH TIKVA, Israel, August 25, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule dr
Read more →CANFCan-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study 28-day study in hospitalized patients with moderate COVID-19 symptoms Piclidenoson is an anti-inflammatory drug with a well-es
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study PETACH TIKVA, Israel, July 27, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs tha
Read more →CANFCan-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds An in vitro biological assay that can fish' clinically active cannabis derived compounds with potential efficacy for the
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds PETACH TIKVA, Israel, July 20, 2020 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drug
Read more →CANFCan-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly Piclidenoson to be evaluated for the treatment of COVID-19 infected patients with moderate symptoms
Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly to be evaluated for the treatment of COVID-19 infected patients with moderate symptoms TIKVA, Israel, July 15, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnolog
Read more →CANFCan-Fite Announces $3.4 Million Registered Direct Offering
Can-Fite Announces $3.4 Million Registered Direct Offering Israel, July 6, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases,
Read more →CANFCan-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period Results confirm 25 mg Namodenoson as optimal dose based on MRI-PDFF
Announces Final Data Analysis from Phase II NASH Study: Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period TIKVA, Israel, June 30, 2020 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of pro
Read more →CANFNOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 5, 2020 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be
OF SPECIAL MEETING OF SHAREHOLDERS BE HELD ON AUGUST 5, 2020 the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be held on Wednesday, August 5, 2020, at 4:00 P.M. Israel time at our o
Read more →CANFCan-Fite Announces $8.0 Million Registered Direct Offering
$8.0 Million Registered Direct Offering TIKVA, Israel, June 10, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announ
Read more →CANFFollowing Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. IND and Phase II protocol expected to be filed by end of June to evaluate COVID-19 infected patients with mode
Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. IND and Phase II protocol expected to be filed by end of June to evaluate COVID-19 infected patients with moderate-to-severe symptoms PETACH TIKVA, Israel, June 9, 2020 -- Can-F
Read more →CANFCan-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer Following meetings with both the U.S. FDA and EM
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Following meetings with both the U.S. FDA and EMA, Can-Fite is ready to submit its protocol and conduct one pivotal tr
Read more →CANFKost Forer Gabbay & Kasierer 144 Menachem Begin Road Tel-Aviv 6492102, Israel Tel: +972-3-6232525 Fax: +972-3-5622555 ey.com REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Direct
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM the Shareholders and Board of Directors of on the Financial Statements have audited the accompanying consolidated balance sheet of Can-Fite Ltd and its subsidiary (the "Company") as of December 31, 2019 and 2018, and the relate
Read more →CANFCan-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office Patent allowance follows compelling Phase II data showing Namodenoson resolved all cases
Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office allowance follows compelling Phase II data showing Namodenoson resolved all cases of NASH after 12 weeks of treatment, and it reduced hepatic fibrosis and
Read more →CANFCan-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis All cases of NASH significantly resolved after 12 weeks of treatment with N
Reports Additional Findings from Successful Phase II NASH Study: mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis TIKVA, Israel, May 18, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of propri
Read more →CANFCan-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms Piclidenoson's anti-viral, anti-inflammatory, anti-rheumatic properties a
Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the potential treatment of COVID
Read more →CANFCan Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately Study will treat 40 COVID-19 infected patients hospitalized with moderate-to-severe symptoms Efficac
Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately TIKVA, Israel, April 13, 2020 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molec
Read more →CANFCan-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson Main study endpoints were dose dependent and significantly achieved Prof. Safadi, principal investigator: "The study shows Namodeno
Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson TIKVA, Israel, April 7, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory
Read more →CANFNOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 21, 2020 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be
OF SPECIAL MEETING OF SHAREHOLDERS BE HELD ON APRIL 21, 2020 the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): is hereby given that a Special Meeting of Shareholders will be held on Tuesday, April 21, 2020, at 4:00 P.M. Israel time at our offices, 1
Read more →CANFCan-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020 TIKVA, Israel, March 30, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflamma
Read more →CANFCan-Fite Reports 2019 Financial Results & Provides Clinical Development Update Piclidenoson has been submitted for the treatment of coronavirus under compassionate use program in Israel Top-line data from Phase II Namode
Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update PETACH TIKVA, Israel, March 27, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address canc
Read more →CANFCan-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel Rationale: Anti-Rheumatic and Ant-Viral Effects with Excellent Safety Profile
Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel Rationale: Anti-Rheumatic and Ant-Viral Effects with Excellent Safety Profile PETACH TIKVA, Israel, March 23, 2020 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI),
Read more →CANFCan-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment Meetings with prospective partners regarding Piclidenoson as a pote
Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment Meetings with prospective partners regarding Piclidenoson as a potential treatment for coronavirus, in addition to establish
Read more →CANFCan-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson Results indicate Namodenoson has a good safety profile and is well tolerated in patients under compassionate use Tw
Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson TIKVA, Israel, March 16, 2020 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflamm
Read more →CANFCan-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University Can-Fite to Support Research Directed by Kamel Khalili, Ph.D. on Piclidenoson agai
Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University Can-Fite to Support Research Directed by Kamel Khalili, Ph.D. on Piclidenoson against Coronaviruses PETACH TIKVA, Israel, March 13, 2020
Read more →CANFCan-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD Findings point towards potential weight loss upon utilization of nano molar CBD concentrations Can Fite experience i
Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD PETACH TIKVA, Israel, March 11, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecul
Read more →CANF(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation March 2020 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement 2 This presentation contains forward - looking statements
(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation March 2020 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement 2 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions re
Read more →CANFCan-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus Interim analysis d
Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus TIKVA, Israel, March 5, 2020 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI),
Read more →CANFCan-Fite is filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson Favorable safety profile is a substantial benefit in the treatment of chron
is filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and profile is a substantial benefit in the treatment of chronic diseases that require long-term dosing PETACH TIKVA, Israel, March 03, 2020 -- Can-Fite BioPh
Read more →CANFPre-clinical Studies Demonstrate CBD's Robust Anti-Cancer Effect Against Liver Cancer; Can Fite and Univo Pharmaceuticals Expand Collaboration Agreement In pre-clinical studies, CBD enriched fractions induced anti-liver
Studies Demonstrate CBD's Robust Anti-Cancer Effect Against Liver Cancer; Can Fite and Univo Pharmaceuticals Expand Collaboration TIKVA, Israel, February 27, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of propr
Read more →CANFCan Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications Namodenoson may create powerful combination treatment with checkpoint inhibitors currently on the market
Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications PETACH TIKVA, Israel, February 24, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of proprietary smal
Read more →CANFCan-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter Can Fite has out licensed Namodenoson for the treatment of NASH to CKD in Korea
Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter TIKVA, Israel, February 18, 2020 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary s
Read more →CANFNOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 20, 2020 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Sharehold
NOTICE OF SPECIAL GENERAL MEETING OF TO BE HELD ON FEBRUARY 20, 2020 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be held on Thursday, February 20, 2020, at 3:00 P.M. Israel
Read more →CANFCan-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson - Can-Fite successfully concluded its End-of-Phase II meeting with the U.S. FDA recently - One Phase III trial for concurrent
Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson PETACH TIKVA, Israel, February 13, 2020 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr
Read more →CANFCan-Fite BioPharma Announces Pricing of $5 Million Public Offering
PETACH TIKVA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the pricing of
Read more →CANFCan-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis Interim analysis by IDMC intended to improve study's efficiency and accelerate path towards regulatory appro
Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis PETACH TIKVA, Israel, February 3, 2020 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecul
Read more →CANFCan-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects Findings suggest use of cannabinoid-based drugs to treat diseases in whi
Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects PETACH TIKVA, Israel, January 16, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company
Read more →CANFNOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 13, 2020 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Sharehold
NOTICE OF SPECIAL GENERAL MEETING OF TO BE HELD ON FEBRUARY 13, 2020 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be held on Thursday, February 13, 2020, at 3:00 P.M. Israel
Read more →CANFCan-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million
Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million PETACH TIKVA, Israel, January 9, 2020 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver
Read more →CANFData from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer Dr. Stemmer, the study principal investigator currently treating liver cancer patients under compassion
from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer Dr. Stemmer, the study principal investigator currently treating liver cancer patients under compassionate use program FDA has agreed recently with the Company on
Read more →CANFCan-Fite CEO Issues Letter to Shareholders Q1 2020: Topline results from NASH Phase II study expected Advanced stage clinical pipeline positioned to potentially generate more non-dilutive funding through out-licensing di
Can-Fite CEO Issues Letter to Shareholders PETACH TIKVA, Israel, January 06, 2020 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, issued a
Read more →CANFNew Data From Hadassah Medical Center Lab Show Can-Fite's Namodenoson Induces Weight Loss Findings combined with Namodenoson's good safety profile support its potential utilization as an anti-obesity drug PCT Patent appl
Data From Hadassah Medical Center Lab Show Can-Fite's Namodenoson Induces Weight Loss TIKVA, Israel, January 3, 2020 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer
Read more →CANFGolan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing Golan Bitton will contribute his skills acquired through long servi
Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing PETACH TIKVA, Israel, December 26, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology compan
Read more →CANFCan-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial Psoriasis therapeutic market estimated to reach $11.4B in 2020 Distribution deals for the psoriasis indication are in place for Canada, China, Ko
Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial Psoriasis therapeutic market estimated to reach $11.4B in 2020 Distribution deals for the psoriasis indication are in place for Canada, China, Korea and European countries PETACH TIKVA, Israel, Decem
Read more →CANFCan-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update Reached agreement with U.S. FDA on Phase III liver cancer study design & initiated compassionate use program in Israel Signed new distribut
Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, November 29, 2019 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address
Read more →CANFCan-Fite Granted Patents for its Sexual Dysfunction Drug The drug's unique mechanism of action will allow potential treatment in diabetic patients
Can-Fite Granted Patents for its Sexual Dysfunction Drug mechanism of action will allow potential treatment in diabetic patients PETACH TIKVA, Israel, November 19, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of propriet
Read more →CANFCan-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market Company currently evaluating potential partnerships with animal health pharmaceutical
Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, this Indication for Animal Health Market TIKVA, Israel, November 11, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule dru
Read more →CANF2019 ANNUAL GENERAL MEETING OF SHAREHOLDERS
2019 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 12, 2019 To the shareholders of Can-Fite BioPharma Notice is hereby given that the 2019 Annual General Meeting of Shareholders will be held on Thursday, December 12, 2019, at 12:00 p.m. Israel time at our off
Read more →CANFCan-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients Based on encouraging Phase II results, patients with underlying CPB7 cirrhosis who lack a viable
Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients Based on encouraging Phase II results, patients with underlying CPB7 cirrhosis who lack a viable treatment option are now provided Namodenoson The Compan
Read more →CANFU.S. FDA Agreed with Can-Fite's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer Successful conclusion of an End of Phase I
U.S. FDA Agreed with Can-Fite's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in Successful conclusion of an End of Phase II meeting with the FDA PETACH TIKVA, Israel, October 31, 2019 -- Can-Fite BioPharma
Read more →CANFand Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson
and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis TIKVA, Israel, October 17, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company wit
Read more →CANFCan-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson Topline results expected Q1 2020
Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson PETACH TIKVA, Israel, October 15, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver a
Read more →CANFCan Fite Announces Publication of Namodenoson NASH Mechanism of Action in International Journal of Molecular Medicine In pre-clinical studies Namodenoson significantly reduced liver inflammation and fibrosis via de-regul
Fite Announces Publication of Namodenoson NASH Mechanism of Action in International Journal of Molecular Medicine TIKVA, Israel, October 10, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs
Read more →CANFCan-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference International Liver Cancer Association (ILCA) is devoted exclusively to liver cancer research A Phase III study
Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference TIKVA, Israel, September 23, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addres
Read more →CANFCan-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays Cannabinoids bind to A3AR, the target of Can-Fite's drugs Can-Fite's unparalleled expertise in t
Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays PETACH TIKVA, Israel, September 10, 2019 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of propriet
Read more →CANF(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation September 2019 (NYSE American: CANF) (TASE:CFBI)
(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation September 2019 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement 2 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intention
Read more →CANFOPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included els
AND FINANCIAL REVIEW AND PROSPECTS should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in accordance
Read more →CANFCan-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up t
Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, August 29, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address
Read more →CANFCan-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel Drug supply for compassionate use has been manufactured and is ready for use Namodenoson has both Fast Track and
to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel TIKVA, Israel, August 6, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addres
Read more →CANFCan-Fite Signs Agreement with Kyongbo Pharm for the Distribution in South Korea of Piclidenoson in the Treatment of Psoriasis - Up to $4,000,000 in upfront and milestone payments, plus a transfer price for delivering fin
Signs Agreement with Kyongbo Pharm for the Distribution in South Korea of Piclidenoson in the Treatment of Psoriasis TIKVA, Israel, August 1, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small mol
Read more →CANFFindings from Can-Fite's Phase
Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session Phase III study protocol for Namodenoson in the treatment of advanced liver cancer patients is now being prepared and will be presented to FDA in an End of Phase II
Read more →CANFCan-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update Preparatory work for an end-of-Phase II FDA meeting to initiate a Phase III study in liver cancer is ongoing Top-line data from Phase II NA
Reports First Quarter 2019 Financial Results & Provides Clinical Update TIKVA, Israel, May 29, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and infl
Read more →CANFThe anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin The podium presentation will be in a session of Selected Abstracts of Excellence' Top line data from Can-Fite
Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin PETACH TIKVA, Israel, May 23, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that ad
Read more →CANFCan-Fite BioPharma Announces $6 Million Registered Direct Offering
PETACH TIKVA, Israel, May 20, 2019 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has ent
Read more →CANFCan-Fite's Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA) The International Liver Cancer Association (ILCA) Annual Conference has selected the Can-Fite abstract for
Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA) TIKVA, Israel, May 20, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address c
Read more →CANFCan-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson Fast Track and Orphan Drug Status; No treatment currently exists for advanced liver cancer
Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Track and Orphan Drug Status; No treatment currently exists for advanced liver cancer patients in whom the current standard of TIKVA, Israel, May 6, 2019 - Can-Fite BioPh
Read more →CANFCan-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea $2 million received from CKD to date for Namodenoson in the treatment of liver cancer and
Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea $2 million received from CKD to date for Namodenoson in the treatment of liver cancer and NASH PETACH TIKVA, Israel, April 15, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:
Read more →CANFCan-Fite Announces Late-Breaking Abstract Presentation on Namodenoson Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting - Acceptance for late breaking oral presentation underscores t
Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting PETACH TIKVA, Israel, April 10, 2019 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company
Read more →CANFCan-Fite BioPharma Announces $3.2 Million Registered Direct Offering
Announces $3.2 Million Registered Direct Offering PETACH TIKVA, Israel, April 2, 2019 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory disea
Read more →CANFCan-Fite Reports 2018 Financial Results & Provides Clinical Update Global distribution deals signed in Europe and China, including Can-Fite's largest deal to date for up to $74.5 M Top-line data from Phase II Namodenoson
Can-Fite Reports 2018 Financial Results & Provides Clinical Update Global distribution deals signed in Europe and China, including Can-Fite's largest deal to date Top-line data from Phase II Namodenoson trial in the treatment of liver cancer supports continuation into Phase I
Read more →CANFCan-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson - The study did not achieve its primary end point of median overall survival in the whole population of 78 pat
Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson Conference call with management scheduled for today, Tuesday March 26 at 8.30 a.m. Eastern time PETACH TIKVA, Israel, March 26, 2019 -- Can-Fite BioPharma Ltd. (NYSE
Read more →CANFCan-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication Up to $6,000,000 in upfront and milestone payments, plus a transfer price for delivering finished product This agreement ext
Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication TIKVA, Israel, February 25, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ca
Read more →CANFCan-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug Company has been granted osteoarthritis patents in numerous major markets
Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug Company has been granted osteoarthritis patents in numerous major markets PETACH TIKVA, Israel, February 4, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI),
Read more →CANF(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation Pnina Fishman, CEO Motti Farbstein, CFO February 2019 (NYSE American: CANF) (TASE:CFBI)
(NYSE American: CANF) (TASE:CFBI) Can - Fite Presentation Pnina Fishman, CEO Motti Farbstein, CFO February 2019 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement 2 This presentation contains forward - looking statements, about Can - Fi
Read more →CANFCan-Fite's Drugs' Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal Can Fite's drugs robustly inhibit the release of inflammatory mediators that induce Cytokine
Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal Can Fite's drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a potentially fatal side effect of CAR-T and othe
Read more →CANFCan-Fite BioPharma CEO Letter to Shareholders Near term milestones include: Advanced Liver Cancer Phase II data release NAFLD/NASH Phase II data release
BioPharma CEO Letter to Shareholders Near term milestones include: TIKVA, Israel, January 24, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and infl
Read more →CANFOF SPECIAL GENERAL MEETING OF SHAREHOLDERS
OF SPECIAL GENERAL MEETING OF SHAREHOLDERS BE HELD ON MARCH 4, 2019 the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): is hereby given that a Special Meeting of Shareholders will be held on Monday, March 4, 2019, at 4:00 P.M. Israel time at our offic
Read more →CANFCan-Fite BioPharma Announces Registered Direct Offering
BioPharma Announces Registered Direct Offering TIKVA, Israel, January 18, 2019 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, tod
Read more →CANFCan-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent Company filed patent application for the utilization of Namodenoson as an anti-obesity drug A Phase II study of Namodenoson is enrolling patients
Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent TIKVA, Israel, January 08, 2019 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflamm
Read more →CANFCan-Fite Enters Into Collaboration Agreement to Explore Namodenoson's Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC Can-Fite to Support Research Directed by Scott Friedman, M.D. on Namodenoson in H
Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson's Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC Can-Fite to Support Research Directed by Scott Friedman, M.D. on Namodenoson in Human Liver Cells PETACH TIKVA, Israel, December 10, 201
Read more →CANFCan-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update Revenues for the Nine Months Ended
Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update for the Nine Months Ended September 30, 2018 Were $3.5 Million Compared to $0.7 Million for the Same Period in 2017 TIKVA, Israel, November 30, 2018 - Can-Fite BioPharma Ltd. (NYSE American: C
Read more →CANFPrior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert - Dr. Josep Llovet is a Key Opinion Leader in the field of liver diseases - Data from Phase II study in advanced liver cancer are
Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert PETACH TIKVA, Israel, November 20, 2018 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address
Read more →CANFDue to Patient Survival Top line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19 Namodenoson seeks to address a major unmet need for Child Pugh B patients with advanced liver cancer Namoden
to Patient Survival Top line Results of the Namodenoson Phase II Liver Cancer Trial Expected Q1/19 Namodenoson seeks to address a major unmet need for Child Pugh B patients with advanced liver cancer Namodenoson has received Fast Track Status in the U.S. and Orphan Drug Des
Read more →CANFANNUAL GENERAL MEETING OF SHAREHOLDERS
ANNUAL GENERAL MEETING OF SHAREHOLDERS BE HELD ON DECEMBER 3, 2018 the shareholders of Can-Fite BioPharma Ltd.: is hereby given that the 2018 Annual General Meeting of Shareholders will be held on Monday, December 3, 2018, at 12:00 p.m. Israel time at our offices, 10 Bareket
Read more →CANFCan-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference PETACH TIKVA, Israel, October 25, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that ad
Read more →CANFCan-Fite CEO to Present as Expert Speaker on Namodenoson at NASH Summit Europe 2018
CEO to Present as Expert Speaker on Namodenoson at NASH Summit Europe 2018 TIKVA, Israel, October 18, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and infla
Read more →CANFCan-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)
to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD) TIKVA, Israel, September 12, 2018 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company
Read more →CANFTop line results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year Namodenoson seeks to address a major unmet need for Child Pugh B patients with advanced liver cancer Namodenoson has receiv
Top line results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year PETACH TIKVA, Israel, September 4, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule d
Read more →CANFCan-Fite Announces Enrollment of First Patient in its Comfort Phase III Trial of Piclidenoson in Psoriasis Study initiation will prompt a milestone payment from the recently signed deal with Gebro Holding Psoriasis Thera
Can-Fite Announces Enrollment of First Patient in its Comfort Phase III Trial of Piclidenoson in Psoriasis PETACH TIKVA, Israel, August 21, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small mol
Read more →CANFCAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2017 INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Statements of Financial Position
CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2017 Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Statements of Financial Position F-3 F-4 Consolidated Statements of Comprehensive Loss F-5 Cons
Read more →CANFCan-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China Additional milestone and sal
Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China milestone and sales payments total up to $72.5M plus double-digit royalties signed CMS agreeme
Read more →CANFCan-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical Upfront and milestone payments total up to $74.5M plus double-digit royalties CMS will
Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical Upfront and milestone payments total up to $74.5M plus double-digit royalties CMS will be responsible for the development, registration and
Read more →CANFCan-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug Erectile dysfunction market is estimated to reach $3.2 billion by 2022
Granted Australian and Chinese Patents for Erectile Dysfunction Drug dysfunction market is estimated to reach $3.2 billion by 2022 PETACH TIKVA, Israel, July 17, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of
Read more →CANFDrugs with Mechanism of Action Utilized by Namodenoson are recommended by Leading U.S. Researchers to be Developed to Combat Liver Cancer A third party validation for the Can-Fite scientific approach to combat Liver Canc
with Mechanism of Action Utilized by Namodenoson are recommended by Leading U.S. Researchers to be Developed to Combat Liver Cancer PETACH TIKVA, Israel, July 2, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of
Read more →CANFCan-Fite Updates on Status of Phase II Advanced Liver Cancer Trial Accumulated safety data to date continues to indicate a favorable drug safety profile without hepatotoxicity Namodenoson has an Orphan Drug Designation i
Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial PETACH TIKVA, Israel, June 19, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and
Read more →CANFCan-Fite Reports on New Pre-clinical Developments with its NASH Drug Namodenoson Robust anti-NASH effects when drug is administered orally Data support the selection of the primary endpoint for the ongoing Phase II study
Can-Fite Reports on New Pre-clinical Developments with its NASH Drug Namodenoson Robust anti-NASH effects when drug is administered orally Data support the selection of the primary endpoint for the ongoing Phase II study Enrollment for the Phase II study is expected to be
Read more →CANFCan-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update - Company Received upfront payment of $2.2M as Part of Distribution Agreement for Piclidenoson in 3 European Countries - Namodenoson Phas
Reports First Quarter 2018 Financial Results and Provides Clinical Update Company Received upfront payment of $2.2M as Part of Distribution Agreement for Piclidenoson in 3 European Countries Namodenoson Phase II Liver Cancer, Phase II NAFLD/NASH and Phase III Rheumatoid Arthrit
Read more →CANFPiclidenoson Mechanism of Action in Psoriasis Published in Journal of Immunology Research'
Piclidenoson Mechanism of Action in Psoriasis Published in Journal of Immunology Research' III Psoriasis Study Scheduled for Initiation During this Quarter Therapeutic Market is Estimated to Reach $11.4B in 2020 TIKVA, Israel, April 25, 2018 -- Can-Fite BioPharma Ltd. (NYSE Am
Read more →CANFCan-Fite Reports 2017 Financial Results & Provides Clinical Update Ø A multi-million dollar agreement has been signed with Gebro Holdings for the distribution of Piclidenoson in 3 European Countries Ø Phase
Reports 2017 Financial Results & Provides Clinical Update TIKVA, Israel, March 23, 2018 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammat
Read more →CANFCan-Fite BioPharma Announces $5 Million Registered Direct Offering
BioPharma Announces $5 Million Registered Direct Offering TIKVA, Israel, March 9, 2018 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, to
Read more →CANFCan-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30 th Annual ROTH Conference Renowned Key Opinion Leaders will participate in the NASH panel discussions Yet no FDA approved drug fo
to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference TIKVA, Israel, March 6, 2018 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs
Read more →CANFCan Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson Accumulated safety data to date indicates potential favorable drug safety profile without hepatotoxicity Company anticipates dat
Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson TIKVA, Israel, February 28, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address c
Read more →CANFCan Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile The findings allow the continuation of the ongoing Phase II an
Fite Announces the Submission of Safety Reports for Piclidenoson Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile The findings allow the continuation of the ongoing Phase II and Phase III clinical studies The differential effect of the d
Read more →CANFCan Fite BioPharma Announces New Pre-clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson Pre-clinical studies show Namodenoson's mechanism of action in inhibiting inflammation and fibrosis in N
Fite BioPharma Announces New Pre-clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson TIKVA, Israel, February 12, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molec
Read more →CANFCan-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries Additional milestone payments of up to $7,000,000 and double digit royalty payments on n
Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries milestone payments of up to $7,000,000 and double digit royalty payments on net sales upon the achievement of certain regulatory, launch and sales milesto
Read more →CANFNOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 22, 2018 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Sharehold
SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 22, 2018 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): given that a Special Meeting of Shareholders will be held on Thursday, February 22, 2018, at 4:00 P.M. Israel time at our o
Read more →CANFCan-Fite 12 Months Activities & Milestones for 2018 Expected milestones in the next 12 months include: Two Phase III studies in rheumatoid arthritis and psoriasis Data release from the Phase II liver cancer trial Complet
12 Months Activities & Milestones for 2018 milestones in the next 12 months include: TIKVA, Israel, January 11, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address canc
Read more →CANFCan-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings Agreement includes upfront and milestone payments, plus royalties
Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings includes upfront and milestone payments, plus royalties TIKVA, Israel, January 8, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology c
Read more →CANFCan-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH Namodenoson improves steatosis, inflammation and ballooning in pre-clinical st
Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in Namodenoson improves steatosis, inflammation and ballooning in pre-clinical studies A Phase II study of Namodenoson is enrolling NAFLD/NASH patien
Read more →CANFCan Fite Reports on the Progress of its Phase II Liver Cancer with Namodenoson Accumulated safety data to date indicates potential favorable drug safety profile without hepatotoxicity Company anticipates data release to
Can Fite Reports on the Progress of its Phase II Liver Cancer with Namodenoson PETACH TIKVA, Israel, December 18, 2017 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address c
Read more →CANFCan-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update Namodenoson: Commences enrollment in Phase II NAFLD/NASH trial Completes enrollment in Phase II liver cancer trial Receives milestones paym
Reports Third Quarter 2017 Financial Results & Provides Clinical Update TIKVA, Israel, November 27, 2017 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and infl
Read more →CANFCan-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson Data show Namodenoson's efficacy in reducing liver fat and fibrosis in NASH models No FDA approved drug yet for NASH indication, an unmet medic
Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson PETACH TIKVA, Israel, November 27, 2017 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address can
Read more →CANFCan-Fite's Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma
Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma PETACH TIKVA, Israel, November 17, 2017 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that ad
Read more →CANFSPECIAL GENERAL MEETING OF SHAREHOLDERS
SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 21, 2017 To the shareholders and ADS holders of Can-Fite BioPharma Ltd. (the "Company"): Notice is hereby given that a Special Meeting of Shareholders will be held on Wednesday, December 21, 2017, at 4:00 P.M. Is
Read more →CANFCan-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis Piclidenoson is being developed as a first line therapy and replacement for the current standard of ca
Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis TIKVA, Israel, October 30, 2017 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule
Read more →CANFCan-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis Can-Fite has distribution agreements in Korea for Piclidenoson and Namodenoson Piclidenoson slated to enter Phase III study in treatment of p
Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis Can-Fite has distribution agreements in Korea for Piclidenoson and Namodenoson Piclidenoson slated to enter Phase III study in treatment of psoriasis in 2018 TIKVA, Israel, October 17, 2017 -- Can-Fite B
Read more →CANFCan-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy - The CAR-T market, a growing segment within cancer treatment, is estimated to reach
Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy - The CAR-T market, a growing segment within cancer treatment, is estimated to reach approximately $4.5 Billion in 2022 according to Evaluate Pharma -
Read more →CANFCan - Fite Presentation - September 2017 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, bus
Can - Fite Presentation - September 2017 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategi
Read more →CANFCan-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update Phase II Liver Cancer Trial for Namodenoson Successfully Completes Patient Enrollment Milestone Payment Received for Namodenoson Liver Can
Reports Second Quarter 2017 Financial Results & Provides Clinical Update TIKVA, Israel, September 1, 2017 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and canc
Read more →CANFCan-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea - Deal provides for up to $3,000,000 in upfront and milestone payments & 23% royalties - Agreement includes distributor's rig
Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea TIKVA, Israel, August 23, 2017 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cance
Read more →CANFCan-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer Namodenoson has been granted Orphan Drug Designation in Europe and the U.S. and Fast Track Status in the U.S. as
Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer Namodenoson has been granted Orphan Drug Designation in Europe and the U.S. and Fast Track Status in the U.S. as a second line treatment for hepatocellular carcinoma (HCC) Base
Read more →CANFCan-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson Strong safety results clear Piclidenoson to commence Phase III efficacy trials in the treatment of Rheumatoid Arthritis and Psoriasis
Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson safety results clear Piclidenoson to commence Phase III efficacy trials in the treatment of Rheumatoid Arthritis and Psoriasis TIKVA, Israel, August 7, 2017 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TA
Read more →CANFCan-Fite's Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting Compelling unmet need for NAFLD/NASH drug to address estimated $35
Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator unmet need for NAFLD/NASH drug to address estimated $35 billion treatment market by 2025 TIKVA, Israel, July 17 2017 - Can-Fite BioPharma Ltd.
Read more →CANFCan-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis Piclidenoson is being developed as a first line therapy and replacement
Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid is being developed as a first line therapy and replacement for the current standard of care, Methotrexate (MTX), the most widely used drug for rhe
Read more →CANFCan-Fite Establishes Clinical Advisory Board for NAFLD/NASH - Board members are Key Opinion Leaders in the field of liver diseases - Phase II study in NAFLD/NASH expected to commence Q3 2017 - New pre-clinical data demon
Establishes Clinical Advisory Board for NAFLD/NASH TIKVA, Israel, June 5, 2017 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announ
Read more →CANFNew Preclinical Data on Can-Fite's Namodenoson to be Presented at 1 st International Conference on Fatty Liver in Seville, Spain on
Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017 - Data show Namodenoson both prevents and inhibits liver fibrosis - Namodenoson is to be evaluated in upcoming Phase II trial for the treatment of
Read more →CANFCan-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update Phase III trial for rheumatoid arthritis and Phase II trial for NAFLD/NASH to commence patient enrollment
Reports First Quarter 2017 Financial Results & Provides Clinical Update III trial for rheumatoid arthritis and Phase II trial for NAFLD/NASH to commence patient enrollment TIKVA, Israel, May 30, 2017 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology compa
Read more →CANFCan-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study TIKVA, Israel, May 16, 2017 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small mole
Read more →CANFCan-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH - $35 Billion treatment market by 2025 with need for an FDA approved drug - Phase II trial's estimated cost is under $1 Milli
Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH - $35 Billion treatment market by 2025 with need for an FDA approved drug - Phase II trial's estimated cost is under $1 Million - Namodenoson drug supply ready and IRBs have approved protocol
Read more →CANFCan-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board - Barzilai Medical Center in Israel ready to enroll patients - IRB approvals in European and Canadian medical centers expe
Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board TIKVA, Israel, April 25, 2017 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liv
Read more →CANFCan-Fite Reports 2016 Financial Results & Provides Clinical Update - Phase III trial of Piclidenoson in the treatment of rheumatoid arthritis expected to commence in the coming months - Safety profile of Piclidenoson wel
Reports 2016 Financial Results & Provides Clinical Update - Phase III trial of Piclidenoson in the treatment of rheumatoid arthritis expected to commence in the coming months - Safety profile of Piclidenoson well suited to meet market need for long-term treatment of auto-immun
Read more →CANFNew Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis - Phase II trial to treat NAFLD/NASH expected to commence in 2017 - Lowering liver fat content and fibrosis are the main unm
Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis - Phase II trial to treat NAFLD/NASH expected to commence in 2017 liver fat content and fibrosis are the main unmet needs in NASH, according to KOL Dr. Rifaat Safadi TIKVA, Israel, Febr
Read more →CANFCan-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis - Patient enrollment to commence Q2 2017 - - Piclidenoson supply for the study is completed and paid for - - Total budget for the
Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis TIKVA, Israel, February 8, 2017 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver
Read more →CANFCan-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017 Compelling unmet need for NAFLD/NASH drug due to lack of FDA approved drug for the indication and an estimated $35 bil
Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017 unmet need for NAFLD/NASH drug due to lack of FDA approved drug for the indication and an estimated $35 billion treatment market TIKVA, Israel, January 9, 2017 -- Can-Fite BioPharma L
Read more →CANFCan - Fite Presentation - January 2017 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, busin
Can - Fite Presentation - January 2017 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies
Read more →CANFCan-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea Additional $2.5 million in milestone payments plus 23% royalties upon commercialization
$500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea Additional $2.5 million in milestone payments plus 23% royalties upon commercialization in South Korea PETACH TIKVA, Israel, December 21, 2016 -- Can-Fite BioPhar
Read more →CANFNew Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis - Supports Potential Efficacy in Treatment of NASH Phase II trial to treat NAFLD/NASH expected to commence in 2017
Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis - Supports Potential Efficacy in Treatment II trial to treat NAFLD/NASH expected to commence in 2017 TIKVA, Israel, December 16, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotech
Read more →CANFCan-Fite Reports Financial Results for Nine Months Ended
Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update TIKVA, Israel, November 25, 2016 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to
Read more →CANFAmerican Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102
Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102 TIKVA, Israel, November 16, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary
Read more →CANFCan-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug Broad patent coverage for both composition of matter & specific receptor ligands for the treatment of erectile dys
Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug patent coverage for both composition of matter & specific receptor ligands for the treatment of erectile dysfunction TIKVA, Israel, November 9, 2016 -- Can-Fite BioPharma Ltd. (NYSE
Read more →CANFCAN-FITE BIOPHARMA LTD. PROXY FOR A SPECIAL GENERAL MEETING OF SERIES 10 WARRANT HOLDERS TO BE HELD ON DECEMBER 8, 2016 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Pni
FOR A SPECIAL GENERAL MEETING SERIES 10 WARRANT HOLDERS BE HELD ON DECEMBER 8, 2016 PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. undersigned hereby appoints Dr. Pnina Fishman, Chief Executive Officer, Motti Farbstein, Chief Operating and Financial Officer, and Ron
Read more →CANFCan-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA - Phase III clinical study designed to establish Piclidenoson is superior to place
Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with (CF101) Following Reaching Agreement with EMA - Phase III clinical study designed to establish Piclidenoson is superior to placebo as primary endpoint and non-inferior to Otezla at week 32 as secondary endpo
Read more →CANFCan-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea Deal provides for up to $3,000,000 in upfront and milestone payments & a percentage rate of royalty payments in the low twenties Includes right
Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea Deal provides for up to $3,000,000 in upfront and milestone payments & a percentage rate of royalty payments in the low twenties Includes right of first refusal to distribute CF102 for other indications inclu
Read more →CANFCan-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH Leading Israeli medical institutions Hadassah and Rabin Medical Centers to be included in the trial Study to enroll 60 patients with pr
Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH Leading Israeli medical institutions Hadassah and Rabin Medical Centers to be included in the trial Study to enroll 60 patients with primary endpoint of reducing liver fat $35 billion estimated tre
Read more →CANFCan-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal Article published in Molecular Medicine Reports CF102 is currently in global Phase II trial for liver cancer
Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal TIKVA, Israel, September 20, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being d
Read more →CANFCan-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial 2.4 million Europeans living with moderate-to-severe psoriasis Global psoriasis market projected to reach $13.3 billion by 202
Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial 2.4 million Europeans living with moderate-to-severe psoriasis Global psoriasis market projected to reach $13.3 TIKVA, Israel, September 13, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT
Read more →CANFCAN-FITE BIOPHARMA LTD. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2016 UNAUDITED INDEX Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Condensed Consolidated St
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Condensed Consolidated Statements of Comprehensive Loss 4 Interim Condensed Consolidated Statements of Changes in Equity 5 - 6 Interim Condensed Consol
Read more →CANFReports Financial Results for Six Months Ended June 30, 2016
Reports Financial Results for Six Months Ended June 30, 2016 update on treatments for rheumatoid arthritis, psoriasis, liver cancer, NASH and sexual dysfunction TIKVA, Israel, August 26, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with
Read more →CANFCompletes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD
Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD - NASH/NAFLD are the leading cause of liver disease in Western countries - $35 billion estimated global market for NASH by 2025 - Compelling pre-clinical data indicate hepato-protective drug CF102 may be
Read more →CANFOphthaliX Announces Phase II Glaucoma Data
OphthaliX Announces Phase II Glaucoma Data PETACH TIKVA, Israel, July 5, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual
Read more →CANFCan-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects - Similar to biologics, Piclidenoson (CF101) inhibits inflammatory proteins IL-17
Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects TIKVA, Israel, June 15, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small
Read more →CANFCan-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) - Phase III protocol is a head-to-head trial comparing Piclidenoson to Otezla - Former Phase II/III study showed Piclide
Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) - Phase III protocol is a head-to-head trial comparing Piclidenoson to Otezla - Former Phase II/III study showed Piclidenoson has better safety and efficacy at week 32 as compared to Ote
Read more →CANFCan-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis - EMA suggests development of Piclidenoson as a first line therapy and alternative for methotrexat
Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis PETACH TIKVA, Israel, June 1, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small mo
Read more →CANFCan-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update
Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update TIKVA, Israel, May 27, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammato
Read more →CANFCan-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose CF602 may provide benefits for patients who cannot take or do not res
Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After may provide benefits for patients who cannot take or do not respond to erectile dysfunction drugs currently on the market TIKVA, Israel, April 11, 20
Read more →CANFCan-Fite Reports 2015 Financial Results & Provides Clinical Pipeline Update
Reports 2015 Financial Results & Provides Clinical Pipeline Update TIKVA, Israel, April 1, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, c
Read more →CANFCan-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis Trial expected to commence in Q2/3 of 2016
Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis expected to commence in Q2/3 of 2016 TIKVA, Israel, March 17, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechn
Read more →CANFU.S.
U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602 - Composition of matter patent protects use of an A3AR modulator for the treatment of any indication PETACH TIKVA, Israel, January 19, 2016 -- Can-Fite BioPharma Ltd. (NYSE
Read more →CANFCan - Fite Presentation - January 2016 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, busin
Can - Fite Presentation - January 2016 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies
Read more →CANFCan-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis Pivotal Phase III trial to enroll approximately 456 patients for robust statistically significant data Phase III protocol subm
Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis Pivotal Phase III trial to enroll approximately 456 patients for robust statistically significant data Phase III protocol submission follows Can-Fite's successful meeting with the Medical Pr
Read more →CANFCan-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma CF101's Phase II glaucoma trial recently completed enrollment Glaucoma market is estimated to reach $3 billion by 2023
CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma Phase II glaucoma trial recently completed enrollment Glaucoma market is estimated to reach $3 billion by 2023 TIKVA, Israel, December 17, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI
Read more →CANFCan-Fite Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101 CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in
Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023 TIKVA, Israel, December 7, 2015 -- Can-Fite BioPharma Ltd. (NYSE M
Read more →CANFReports Financial Results for Nine Months Ended September 30, 2015
Reports Financial Results for Nine Months Ended September 30, 2015 developments with CF102 in liver cancer and NASH, plus three additional indications for CF101 and CF602 in Rheumatoid Arthritis, Psoriasis and Sexual Dysfunction TIKVA, Israel, November 27, 2015 -- Can-Fite Bi
Read more →CANFCan-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Files patent for CF102 in the treatment of NASH Large unmet need for 2-5% of U.S. population living with N
Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis (NASH) patent for CF102 in the treatment of NASH unmet need for 2-5% of U.S. population living with NASH $35-40 billion market by 2025 FDA approved therapies currently exist TI
Read more →CANFCan-Fite BioPharma Ltd. Instructions to The Bank of New York Mellon, as Depositary (Must be received prior to 5:00 p.m. EST on
to The Bank of New York Mellon, as Depositary be received prior to 5:00 p.m. EST on November 18, 2015) undersigned registered owner of American Depositary Shares hereby requests and instructs The Bank of New York Mellon, as Depositary, to endeavor, in so far as practicable, to
Read more →CANFNew Study Demonstrates CF602 Mechanism of Action to Improve Sexual Dysfunction IND submission to FDA is planned for Q3 2016
New Study Demonstrates CF602 Mechanism of Action to Improve Sexual Dysfunction IND submission to FDA is planned PETACH TIKVA, Israel, October 22, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecul
Read more →CANFCan-Fite BioPharma Announces $4.8 Million Registered Direct Offering Continued Investment from Existing Institutional Investors $13.8 million raised in Two Offerings
BioPharma Announces $4.8 Million Registered Direct Offering Continued Investment from Existing Institutional Investors $13.8 million raised in Two Offerings TIKVA, Israel, October 13, 2015 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company adva
Read more →CANFEuropean Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer 10-year market exclusivity in Europe following marketing authorization in 31 European Economic Area (EEA) countries
Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer 10-year market exclusivity in Europe following marketing authorization in 31 European Economic Area (EEA) countries PETACH TIKVA, Israel, October 12, 2015 -- Can-Fite BioPharma L
Read more →CANFCan-Fite to Present CF101 Psoriasis Data at Late Breaking Session of the EADV Congress in Copenhagen on
to Present CF101 Psoriasis Data at Late Breaking Session of the Congress in Copenhagen on October 10, 2015 Breaking Session features very important papers with high impact factors TIKVA, Israel, September 29, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biot
Read more →CANFCan-Fite BioPharma Announces $9 Million Registered Direct Offering
Can-Fite BioPharma Announces $9 Million Registered Direct Offering PETACH TIKVA, Israel, September 20, 2015 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflamm
Read more →CANFU.S. Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer Global market for liver cancer drugs is projected to exceed $2 billion in 2015
Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer Global market for liver cancer drugs is projected to exceed $2 billion in 2015 PETACH TIKVA, Israel, September 17, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF)
Read more →CANFCAN-FITE BIOPHARMA LTD. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2015 UNAUDITED INDEX Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Condensed Consolidated St
CAN-FITE BIOPHARMA LTD. INTERIM CONDENSED CONSOLIDATED FINANCIAL Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Condensed Consolidated Statements of Comprehensive Loss 4 Interim Condensed Consolidated Statements of Changes in Equity 5 - 6 In
Read more →CANFCan-Fite Reports Financial Results for Six Months Ended
Reports Financial Results for Six Months Ended June 30, 2015 development update on advancing three drug candidates through four indications TIKVA, Israel, August 27, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of propri
Read more →CANFWorld Health Organization Accepted "Piclidenoson" as Proposed New Generic Name for Can-Fite's Lead Drug Candidate CF101
Organization Accepted "Piclidenoson" as Proposed New Generic Name for Can-Fite's Lead Drug Candidate CF101 PETACH TIKVA, Israel, July 29, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs t
Read more →CANFCan-Fite's CF602 Sexual Dysfunction Drug Backed by New Preclinical Data Progresses Towards an IND The Company aims to file an IND with the FDA to allow the initiation of a Phase I clinical study
CF602 Sexual Dysfunction Drug Backed by New Preclinical Data Progresses Towards an IND Company aims to file an IND with the FDA to allow the initiation of a Phase I clinical study Israel, June 29, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology co
Read more →CANFCan-Fite Subsidiary OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd. Strategic acquisition to combine medical devices and pharmaceutical products to address multi-billion dollar markets in tre
Subsidiary OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd. acquisition to combine medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic TIKVA, Israel, June 19, 2015 -- Can-Fite BioPharma Ltd. (NYS
Read more →CANFCan-Fite to Exhibit at Bio International Convention in Philadelphia on June 15 - 18, 2015
to Exhibit at Bio International Convention in Philadelphia on June 15 - 18, 2015 TIKVA, Israel, June 15, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammato
Read more →CANFCan-Fite Granted Notice of Allowance for Patent Covering Manufacturing Process of CF101 in the U.S. The patent covers a superior method of manufacturing CF101 potentially increasing future drug profit margin
Granted Notice of Allowance for Patent Covering Manufacturing Process of CF101 in the patent covers a superior method of manufacturing CF101 potentially increasing future drug profit TIKVA, Israel, June 10, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotech
Read more →CANFCan-Fite's Phase II Liver Cancer Trial Approved in Europe First patient dosed in Europe The global market for liver cancer is projected to exceed $2 billion in 2015
Phase II Liver Cancer Trial Approved in Europe The global market for liver cancer is projected to exceed $2 billion in 2015 PETACH TIKVA, Israel, May 11, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small
Read more →CANFCan-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd. New OphthaliX strategy aims to combine ophthalmic medical devices and pharmaceutical products to address multi-billion dollar marke
Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd. OphthaliX strategy aims to combine ophthalmic medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases TIKVA, Israel, May 4, 20
Read more →CANFCan-Fite Reports Positive Results from Further Analysis of Phase II/III Psoriasis Trial Data suggest CF101 as potential first-line systemic therapy for patients with moderate-severe psoriasis; Company prepares protocol o
Positive Results from Further Analysis of Phase II/III Data suggest CF101 as potential first-line systemic therapy for patients with moderate-severe psoriasis; Company prepares protocol of next advanced PETACH TIKVA, Israel, April 27, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT
Read more →CANFCan-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer Designation would provide study protocol assistance and market exclusivity
Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer Designation would provide study protocol assistance and market exclusivity PETACH TIKVA, Israel, April 20, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotec
Read more →CANFCan-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis The Study did not achieve its primary efficacy endpoint
Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis Study did not achieve its primary efficacy endpoint TIKVA, Israel, March 30, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietar
Read more →CANFCan-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals Agreement includes upfront and milestone payments, plus royalties
Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals includes upfront and milestone payments, plus royalties TIKVA, Israel, March 23, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeli
Read more →CANFCan-Fite Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs Patented blood test to be used in clinical trials and as a companion diagnostic for Can-Fite's Drugs
Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs blood test to be used in clinical trials and as a companion diagnostic for Can-Fite's Drugs TIKVA, Israel, March 18, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI),
Read more →CANFCan-Fite BioPharma Ltd.'s CEO Pnina Fishman Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - Mar 5, 2015) - The target is a single receptor found only on abnormal cells -- cancer cells and cells responsible for inflammatory diseases such as psoriasis. The weapon is a platform technology developed by Can-Fite BioPharma Ltd. (NYSE MKT: CAN
Read more →CANFCan-Fite Receives Notice of Allowance in U.S. for Psoriasis Patent Company just completed Phase II/III psoriasis trial and expects to release top line data in Q1 2015
Can-Fite Receives Notice of Allowance in U.S. for Psoriasis Patent Company just completed Phase II/III psoriasis trial and expects to release top line data in Q1 2015 PETACH TIKVA, Israel, February 17, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechno
Read more →CANFCan-Fite Completes Phase II/III Trial for CF101 in Treatment of Psoriasis Data expected to be released in Q1 2015
Completes Phase II/III Trial for CF101 in Treatment of Psoriasis expected to be released in Q1 2015 TIKVA, Israel, February 4, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address
Read more →CANFCan-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies Treated group showed 118% improvement in erectile function measures as compared to placebo
Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies Treated group showed 118% improvement in erectile function measures as compared to placebo PETACH TIKVA, Israel, January 27, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TAS
Read more →CANFCan-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications TIKVA, Israel, January 6, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer a
Read more →CANFCan-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101 The estimated global market of Rheumatoid Arthritis is expected to reach $38B in 2017
Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101 estimated global market of Rheumatoid Arthritis is expected to reach $38B in 2017 TIKVA, Israel, December 30, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotec
Read more →CANFCan-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102 Trial follows successful Phase I/II study which met all study endpoints CF102 granted Orphan Drug Status for this indication by the FDA Global
Doses First Patient in Global Phase II Liver Cancer Trial for CF102 follows successful Phase I/II study which met all study endpoints granted Orphan Drug Status for this indication by the FDA Industry Analysts predict that the global market for liver cancer is projected to exc
Read more →CANFSecond Part of the Glaucoma Phase II study has been Approved in a European Country CF101 is currently one of the few Oral Drugs developed for Glaucoma A US Patent for the utilization of CF101 for Glaucoma Treatment will
Second Part of the Glaucoma Phase II study has been Approved in a European Country CF101 is currently one of the few Oral Drugs developed for Glaucoma A US Patent for the utilization of CF101 for Glaucoma Treatment will be Valid until 2030 The Glaucoma Market Size is estima
Read more →CANFCan-Fite Announces $8 Million At-The-Market Registered Direct Offering
Can-Fite Announces $8 Million At-The-Market Registered Direct Offering Israel, December 2, 2014 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases,
Read more →CANFUS Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101
Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101 TIKVA, Israel, December 1, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule
Read more →CANFCan-Fite Near-Term Milestones Timetable for 2014/2015
Near-Term Milestones Timetable for 2014/2015 TIKVA, Israel, November 18, 2014 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced
Read more →CANFU.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery CF102 has shown to induce healthy liver cell proliferation resulting in improved liv
Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery has shown to induce healthy liver cell proliferation resulting in improved liver status Israel, September 30, 2014 -- Can-Fite BioPharma Ltd. (NYS
Read more →CANFCAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2014 UNAUDITED INDEX Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Cond
CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Condensed Consolidated Statements of Comprehensive Loss 4 Interim Condensed Consolidated Statements of Chang
Read more →CANFCan-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery In preclinical studies, CF102 induces hepatocyte proliferation resulting in improved liver status
Can-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery In preclinical studies, CF102 induces hepatocyte proliferation resulting in improved liver status PETACH TIKVA, Israel, September 5, 2014 -- Can-Fite BioPharma Ltd
Read more →CANFCan-Fite Reports First Six Months 2014 Results
Reports First Six Months 2014 Results TIKVA, Israel, September 2, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial re
Read more →CANFNew Data Shows High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patients BMI analysis shows high efficacy of CF101; The data supports the design of the forthcoming Phase III clinical studies
New Data Shows High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patients BMI analysis shows high efficacy of CF101; The data supports the design of the forthcoming Phase III clinical studies PETACH TIKVA, Israel, August 6, 2014 -- Can-Fite BioPharma L
Read more →CANFCan-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient Patient was previously enrolled in Can-Fite's Phase I/II liver cancer study and has survived for about 5-years using the Company's cancer
Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient Patient was previously enrolled in Can-Fite's Phase I/II liver cancer study and has survived for about 5-years using the Company's cancer drug; The global liver cancer drug market is expected to
Read more →CANFCan-Fite Completes Patient Enrollment in its Phase II/III Psoriasis Trial; Final Results are expected in Q1 2015 Previously released interim results from the trial showed positive safety and efficacy 300 patients with mo
Can-Fite Completes Patient Enrollment in its Phase II/III Psoriasis Trial; Final Results are expected in Q1 2015 Previously released interim results from the trial showed positive safety and efficacy 300 patients with moderate to severe disease were enrolled in the study PE
Read more →CANFCan-Fite Subsidiary OphthaliX Provides an Update on its Clinical Developments and Strategic Plans Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues
Subsidiary OphthaliX Provides an Update on its Clinical Developments and Strategic Plans Petach Tikva, Israel, June 9, 2014 / Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflamm
Read more →CANFCan-Fite Announces that the US FDA has Agreed with its Phase II Liver Cancer Protocol Can-Fite's CF102 has FDA's Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma
Can-Fite Announces that the US FDA has Agreed with its Phase II Liver Cancer Protocol Can-Fite's CF102 has FDA's Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma PETACH TIKVA, Israel, June 2, 2014 - Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE
Read more →CANFNOTICE OF 2014 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 7, 2014 __________________________________________________ To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2014 Ann
__________________________________________________ 2014 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 7, 2014 __________________________________________________ To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2014 Annual General M
Read more →CANFCan-Fite Reports First Quarter 2014 Results
Can-Fite Reports First Quarter 2014 Results PETACH TIKVA, Israel, May 29, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported fin
Read more →CANFCan-Fite Receives Patent in European Union for Treatment of Liver Function Following Surgery Preclinical studies show CF102 helps liver regenerate cells and repair itself following surgery or other injury
Can-Fite Receives Patent in European Union for Treatment of Liver Function Following Surgery Preclinical studies show CF102 helps liver regenerate cells and repair itself following surgery or PETACH TIKVA, Israel, May 7, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE
Read more →CANFCan-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study Tufts University will be a clinical site for international trial of CF102 with Orphan Drug Designation
Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study Tufts University will be a clinical site for international trial of CF102 with Orphan Drug Designation PETACH TIKVA, Israel, April 29, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotec
Read more →CANFCan-Fite Initiates the Development of an A3AR Biomarker Test Kit to Predict Patients' Response to Company's Drugs Patented biomarker test designed to predict, monitor and improve patient outcomes
Initiates the Development of an A3AR Biomarker Test Kit to Predict Patients' Response to Company's Drugs PETACH TIKVA, Israel, April 21, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs th
Read more →CANFCan-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel CF102 has Orphan Drug Designation from U.S. FDA Global Liver Cancer Drug Market is Expected
Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel CF102 has Orphan Drug Designation Global Liver Cancer Drug Market is Expected to Exceed $2 Billion by 2015 Petach Tikva, Israel, March 17, 2014: Can-Fite Bi
Read more →CANFSECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the Agreement ), dated as of
SECURITIES PURCHASE AGREEMENT AGREEMENT (the "Agreement"), dated as of March 10, 2014, by and among Can-Fite BioPharma Ltd., an Israeli limited company, with headquarters located at 10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petach-Tikva 4951778, Israel (the "Company"),
Read more →CANFCan-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program Petach Tikva, Israel
the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program Israel - March 3, 2014 Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer dis
Read more →CANFCan-Fite Granted Patent on the Manufacturing of CF101 in Japan The patent confers exclusive right for the manufacturing of CF101 in Japan until 2028 and bolsters license agreement that Can-Fite has already signed in Japa
Granted Patent on the Manufacturing of CF101 in Japan patent confers exclusive right for the manufacturing of CF101 in Japan until 2028 and bolsters license agreement that Can-Fite has already signed in Japan Petach Tikva, Israel - February 25, 2014 Can-Fite BioPharma Ltd. (T
Read more →CANFCan-Fite Provides Update on Key Milestones for 2014 Petach Tikva, Israel
Update on Key Milestones for 2014 Israel - February 18, 2014 Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the company's developme
Read more →CANFCan-Fite Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer CF102 has Orphan Drug Designation from U.S. FDA Global Liver Cancer Drug Market is Expected to Exceed $2 Billion by 2015
Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer CF102 has Orphan Drug Designation Global Liver Cancer Drug Market is Expected to Exceed $2 Billion by 2015 Petach Tikva, Israel, February 06, 2014: Can-Fite BioPharma (TASE: CFBI), (OTC
Read more →CANFSummary of the Application for Compromise or Settlement: In accordance with the application for approval of the settlement between the Company and its shareholders and the Company and the holders of warrants (Series 7) o
In accordance with the application for approval of the settlement between the Company and its shareholders and the Company and the holders of warrants (Series 7) of the Company (the "Settlement Petition" and / or "Settlement"), the court has been asked to approve the proposed
Read more →CANFCan-Fite to Present New Clinical Data from a Further Analysis of its Clinical Studies of CF101 for the Treatment of Rheumatoid Arthritis and Psoriasis at OneMedForum and Biotech Showcase held in San Francisco, California
Present New Clinical Data from a Further Analysis of its Clinical Studies of CF101 for the Treatment of Rheumatoid Arthritis and Psoriasis at OneMedForum and Biotech Showcase held in San Francisco, California Israel - January 13, 2014 Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE
Read more →CANFIT IS HEREBY RESOLVED: 1. Transition of the Reporting Format of the Company In Accordance With the Provisions of the U.S. Securities Laws It was resolved to approve the transition of the Company from the reporting format
Transition of the Reporting Format of the Company In Accordance With the Provisions of the U.S. Securities Laws was resolved to approve the transition of the Company from the reporting format in accordance with the provisions of the Israeli Securities Law, 1968, to the reportin
Read more →CANFOphthaliX to Retrospectively Analyze the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker Following the Successful Utilization of the A3 Adenosine Receptor Biomarker in Can-Fite's Phase
Retrospectively Analyze the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker Following the Successful Utilization of the A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study Israel - December 31, 2013 Can-Fite Bio
Read more →CANFOphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome Petach Tikva, Israel
Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome Israel - December 30, 2013 Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announ
Read more →CANFCan Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis Petach Tikva, Israel
Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis Israel - December 23, 2013 Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflamma
Read more →CANFCan-Fite BioPharma Granted a U.S. Patent for the Utilization of the A3 Adenosine Receptor as a Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
BioPharma Granted a U.S. Patent for the Utilization of the A3 Adenosine Receptor as a Biomarker to Predict Patient Response CF101 in Autoimmune Inflammatory Indications ISRAEL - December 19, 2013 - Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company d
Read more →CANFCAN-FITE BIOPHARMA LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013 UNAUDITED INDEX Page Review of Interim Consolidated Financial Statements 2 Interim Consolidated Statements of Financial Position
CAN-FITE BIOPHARMA LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2013 Page Review of Interim Consolidated Financial Statements 2 Interim Consolidated Statements of Financial Position 3 - 4 Interim Consolidated Statements of Comprehensive Income 5 Interim
Read more →CANFCan-Fite BioPharma Announces Approval of ADR Listing on NYSE MKT Petach Tikva, Israel
BioPharma Announces Approval of ADR Listing on NYSE MKT Tikva, Israel - November 15, 2013 - Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced
Read more →CANFCAN-FITE BIOPHARMA LTD. 9/30/2013 Unaudited Pro Forma Interim Consolidated Balance Sheet $1 = NIS 3.537 Convenience translation Shares and Into options issuance Proforma data U.S. dollars. September 30, September 30
CAN-FITE BIOPHARMA LTD. 9/30/2013 Unaudited Pro Forma Interim Consolidated Balance Sheet $1 = NIS 3.537 Convenience translation Shares and Into options issuance Proforma data U.S. dollars. September 30, September 30, September 30, 2013 2013 2013 Unaudited Unaudited Unaudited NIS
Read more →CANFU.S. Patent and Trademark Office Grants a Patent for the Reduction of Intraocular Pressure Petach Tikva, Israel
U.S. Patent and Trademark Office Grants a Patent for the Reduction of Intraocular Pressure Petach Tikva, Israel, November 5, 2013 / Can-Fite BioPharma Ltd. (TASE:CFBI), (OTCQB:CANFY), a biotechnology company developing a pipeline of small molecule drugs that address inflammat
Read more →CANFCan-Fite Executes Confidentiality Agreements with Pharmaceutical and Biotechnology Companies with Respect to Potential CF101 Commercialization Negotiations Can-Fite expects to release data from its Phase IIb CF101 study
Executes Confidentiality Agreements with Pharmaceutical and Biotechnology Companies with Respect to Potential CF101 Commercialization expects to release data from its Phase IIb CF101 study in Rheumatoid Arthritis at the end of 2013 Tikva, Israel - November 04, 2013 - Can-Fite B
Read more →CANFCan - Fite Investor Presentation - Fall 2013 Pnina Fishman, PhD CEO Page 2 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, it
Can - Fite Investor Presentation - Fall 2013 Pnina Fishman, PhD CEO Page 2 This presentation contains forward - looking statements, about Can - Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial conditio
Read more →CANFCAN-FITE ANNOUNCES FUND RAISING RESULTS IN SHELF OFFERING COMPLETED ON THE TEL AVIV STOCK EXCHANGE ON OCTOBER 23 RD , 2013 Can Fite Bioharma Ltd. (the " Company ") is pleased to announce the results of a fund raising hel
CAN-FITE ANNOUNCES FUND RAISING RESULTS IN SHELF OFFERING COMPLETED ON THE TEL AVIV STOCK EXCHANGE ON OCTOBER 23RD, 2013 Can Fite Bioharma Ltd. (the "Company") is pleased to announce the results of a fund raising held today, October 23rd 2013, in accordance with the Company's
Read more →CANFCAN-FITE: FUND-RAISING IN ORDER TO SATISFY QUALIFICATION REQUIRMENTS TO REGISTER ON THE NYSE MKT EXCHANGE Investment bank Roth Capital Partners Inc. serves as an advisor of the Company for the purpose of the fund-raising
CAN-FITE: FUND-RAISING IN ORDER TO SATISFY QUALIFICATION REQUIRMENTS TO REGISTER ON THE NYSE MKT EXCHANGE bank Roth Capital Partners Inc. serves as an advisor of the Company for the purpose of the fund-raising American institutional investors have announced their intention t
Read more →CANFCan-Fite BioPharma Announces Expected Clinical Activity Milestones through the end of 2013 and Listing on Major US Stock Exchange Results from Two Clinical Trials at advanced stages is expected in last two weeks of 2013;
BioPharma Announces Expected Clinical Activity Milestones through the end of 2013 and Listing on Major US Stock Exchange from Two Clinical Trials at advanced stages is expected in last two weeks of 2013; and announcement of final results of Dry Eye Syndrome Phase III trial, wit
Read more →CANFCan-Fite BioPharma Announces Clinical and Corporate Developments for Near-Term Events
PETACH TIKVA, ISRAEL--(Marketwired - Oct 22, 2013) - Can-Fite BioPharma (TASE: CFBI), (OTCQB: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today a series of clinical and corporate deve
Read more →CANFAbout Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (the "TASE") (TASE: CFBI). Level II American Depository Receipts o
Subsidiary, OphthaliX, to Present at Ophthalmology Futures European Forum Clinical Data on CF101 for Treatment of Glaucoma TIKVA, ISRAEL - October 2, 2013 - Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company developing a pipeline of small molecule dr
Read more →CANFCAN-FITE BIOPHARMA LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2013 UNAUDITED INDEX Page Review of Interim Consolidated Financial Statements 2 Interim Consolidated Statements of Financial Position 3 - 4
CAN-FITE BIOPHARMA LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS Page Review of Interim Consolidated Financial Statements 2 Interim Consolidated Statements of Financial Position 3 - 4 Interim Consolidated Statements of Comprehensive Income 5 Interim Consolidated Statements of
Read more →CANFCan-Fite's Level II ADRs Commence Trading on the U.S. OTC Markets Petach Tikva, Israel
Level II ADRs Commence Trading on the U.S. OTC Markets Petach Tikva, Israel, September 12, 2013: Can-Fite BioPharma Ltd. (TASE:CFBI), (OTCQB:CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, annou
Read more →Competitive Position
How CANF ranks across every disease it competes inCompetitive Position is a premium feature
See how CANF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial